<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NOVOLOG- insulin aspart injection, solution </strong><br>TYA Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 2000
        <br><br><span class="Sup">®</span><br><br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><dl>
<dt>•</dt>
<dd>NovoLog is an insulin analog indicated to improve glycemic control in adults and children with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus ( ).
                                        <a href="#i4i_section_id_39b8efc2-e5d3-4fb6-a06b-dbbcda3bf7e7">1.1</a>
</dd>
</dl></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>The dosage of NovoLog must be individualized.
                                        </dd>
<dt>•</dt>
<dd>NovoLog should generally be given immediately (within 5-10 minutes) prior to the start of a meal ( ).
                                        <span class="Italics">Subcutaneous injection:</span><a href="#i4i_section_id_df8e7c8f-ee13-4321-8429-165c2eff3d4f">2.2</a>
</dd>
<dt>•</dt>
<dd>: Change the NovoLog in the reservoir at least every 6 days, change the infusion set, and the infusion set insertion site at least every 3 days. NovoLog should not be mixed with other insulins or with a diluent when it is used in the pump ).
                                        <span class="Italics">Use in pumps</span><a href="#i4i_section_id_a770e1c4-6919-4dd1-80c9-af7d306920bb">(2.3</a>
</dd>
<dt>•</dt>
<dd>: NovoLog should be used at concentrations from 0.05 U/mL to 1.0 U/mL insulin aspart in infusion systems using polypropylene infusion bags. NovoLog has been shown to be stable in infusion fluids such as 0.9% sodium chloride ( ).
                                        <span class="Italics">Intravenous use</span><a href="#i4i_section_id_422c6521-2edd-40c4-abb3-25735c59d3d8">2.4</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Each presentation contains 100 Units of insulin aspart per mL (U-100) </p>
<dl>
<dt>•</dt>
<dd>10 mL vials ( )
                                        <a href="#i4i_dosage_form_strength_id_dcf06632-114f-4ddd-bf50-e92db92f8b0a">3</a>
</dd>
<dt>•</dt>
<dd>3 mL PenFill cartridges for the 3 mL PenFill cartridge device ( )
                                        <span class="Sup">®</span><a href="#i4i_dosage_form_strength_id_dcf06632-114f-4ddd-bf50-e92db92f8b0a">3</a>
</dd>
<dt>•</dt>
<dd>3 mL NovoLog FlexPen ( )
                                        <span class="Sup">®</span><a href="#i4i_dosage_form_strength_id_dcf06632-114f-4ddd-bf50-e92db92f8b0a">3</a>
</dd>
<dt>•</dt>
<dd>3 mL NovoLog FlexTouch ( )
                                        <span class="Sup">®</span><a href="#i4i_dosage_form_strength_id_dcf06632-114f-4ddd-bf50-e92db92f8b0a">3</a>
</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Do not use during episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> ( ).
                                        <a href="#i4i_contraindications_id_01bdca45-e233-4653-8c55-7a34ea928495">4</a>
</dd>
<dt>•</dt>
<dd>Do not use in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to NovoLog or one of its excipients.
                                        </dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> is the most common adverse effect of insulin therapy. Glucose monitoring is recommended for all patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.  Any change of insulin dose should be made cautiously and only under medical supervision ( , ).
                                        <a href="#i4i_section_id_09c5c9cf-72ff-45a7-ade3-91bc977b5a4e">5.1</a><a href="#i4i_section_id_6a99b82e-9709-4c93-acf8-0454b9e4464d">5.2</a>
</dd>
<dt>•</dt>
<dd>Insulin, particularly when given intravenously or in settings of poor glycemic control, can cause <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Use caution in patients predisposed to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> ).
                                        <a href="#i4i_section_id_88b35ef8-a0b4-4d7d-bbb8-4e27079c62d1">(5.3</a>
</dd>
<dt>•</dt>
<dd>Like all insulins, NovoLog requirements may be reduced in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> , ).
                                        <a href="#i4i_section_id_4c6ad6e0-abec-45fb-bb1a-1cfe895862c4">(5.4</a><a href="#i4i_section_id_a2a42026-9e15-4c53-886d-dc798f2e7860">5.5</a>
</dd>
<dt>•</dt>
<dd>Severe, life-threatening, generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, may occur with insulin products, including NovoLog ( ).
                                        <a href="#i4i_section_id_782f84f8-a53e-48d2-9fe1-dcc1bab34ab0">5.6</a>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog ( ).
                                        <a href="#ID_4bef2190-6df9-4c0c-b9d7-83c494519310">5.10</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions observed with NovoLog include <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, local <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>, <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> ( ).
                                    <a href="#i4i_adverse_effects_id_178c7422-f521-4313-8741-676470787aca">6</a> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc. at 1-800-727-6500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>The following may increase the blood-glucose-lowering effect and susceptibility to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>: oral antidiabetic products, pramlintide, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, propoxyphene, salicylates, somatostatin analogs, sulfonamide antibiotics ( ).
                                        <a href="#i4i_interactions_id_ddfdb67c-93b9-4d18-8d10-f67a37844f7c">7</a>
</dd>
<dt>•</dt>
<dd>The following may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), atypical antipsychotics ( ).
                                        <a href="#i4i_interactions_id_ddfdb67c-93b9-4d18-8d10-f67a37844f7c">7</a>
</dd>
<dt>•</dt>
<dd>Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin ( ).
                                        <a href="#i4i_interactions_id_ddfdb67c-93b9-4d18-8d10-f67a37844f7c">7</a>
</dd>
<dt>•</dt>
<dd>Pentamidine may cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, which may sometimes be followed by <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> ( ).
                                        <a href="#i4i_interactions_id_ddfdb67c-93b9-4d18-8d10-f67a37844f7c">7</a>
</dd>
<dt>•</dt>
<dd>The signs of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be reduced or absent in patients taking sympatholytic products such as beta-blockers, clonidine, guanethidine, and reserpine ( ).
                                        <a href="#i4i_interactions_id_ddfdb67c-93b9-4d18-8d10-f67a37844f7c">7</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pediatric: Has not been studied in children with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Has not been studied in children with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> &lt;2 years of age
                                        <a href="#i4i_pediatric_use_id_175e45af-b079-495a-bb10-1ca04d00b1da">(8.4).</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Treatment of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Subcutaneous Injection</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Continuous Subcutaneous Insulin Infusion (CSII) by External Pump</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Intravenous Use</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Administration</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Antibody Production</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Mixing of Insulins</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Continuous Subcutaneous Insulin Infusion by External Pump</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with concomitant use of PPAR-gamma agonists</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Subcutaneous Daily Injections</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Continuous Subcutaneous Insulin Infusion (CSII) by External Pump</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Intravenous Administration of NovoLog</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Recommended Storage</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Physician Instructions</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Patients Using Pumps</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 FDA Approved Patient Labeling </a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_83845130-81bc-4e0f-bd80-489124b5a5ad"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39b8efc2-e5d3-4fb6-a06b-dbbcda3bf7e7"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Treatment of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First">NovoLog is an insulin analog indicated to improve glycemic control in adults and children with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_73e1ff2e-eaa5-46c5-98cb-77f43e3785c2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb748d10-63b5-41f8-8a2d-311c2c01e2a8"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing </h2>
<p class="First">NovoLog is an insulin analog with an earlier onset of action than regular human insulin. The dosage of NovoLog must be individualized. NovoLog given by subcutaneous injection should generally be used in regimens with an intermediate or long-acting insulin [ ]. The total daily insulin requirement may vary and is usually between 0.5 to 1.0 units/kg/day. When used in a meal-related subcutaneous injection treatment regimen, 50 to 70% of total insulin requirements may be provided by NovoLog and the remainder provided by an intermediate-acting or long-acting insulin. Because of NovoLog’s comparatively rapid onset and short duration of glucose lowering activity, some patients may require more basal insulin and more total insulin to prevent pre-meal <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> when using NovoLog than when using human regular insulin.
                                    <span class="Italics">see
                                        <a href="#i4i_warnings_precautions_id_4bc7c883-0765-44cd-8028-c744ee1c4853">Warnings and Precautions (5),</a><a href="#i4i_storage_id_af41a3f6-59d7-4db1-a09e-3b81ed0d89f3">How Supplied/Storage and Handling (16.2)</a></span></p>
<p>Do not use NovoLog that is viscous (thickened) or cloudy; use only if it is clear and colorless. NovoLog should not be used after the printed expiration date.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_df8e7c8f-ee13-4321-8429-165c2eff3d4f"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Subcutaneous Injection</h2>
<p class="First">NovoLog should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or upper arm. Because NovoLog has a more rapid onset and a shorter duration of activity than human regular insulin, it should be injected immediately (within 5-10 minutes) before a meal. Injection sites should be rotated within the same region to reduce the risk of <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>. As with all insulins, the duration of action of NovoLog will vary according to the dose, injection site, blood flow, temperature, and level of physical activity.</p>
<p>NovoLog may be diluted with Insulin Diluting Medium for NovoLog for subcutaneous injection. Diluting one part NovoLog to nine parts diluent will yield a concentration one-tenth that of NovoLog (equivalent to U-10). Diluting one part NovoLog to one part diluent will yield a concentration one-half that of NovoLog (equivalent to U-50).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a770e1c4-6919-4dd1-80c9-af7d306920bb"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Continuous Subcutaneous Insulin Infusion (CSII) by External Pump</h2>
<p class="First">NovoLog can also be infused subcutaneously by an external insulin pump [see ]. Diluted insulin should not be used in external insulin pumps. Because NovoLog has a more rapid onset and a shorter duration of activity than human regular insulin, pre-meal boluses of NovoLog should be infused immediately (within 5-10 minutes) before a meal. Infusion sites should be rotated within the same region to reduce the risk of <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>. The initial programming of the external insulin infusion pump should be based on the total daily insulin dose of the previous regimen. Although there is significant interpatient variability, approximately 50% of the total dose is usually given as meal-related boluses of NovoLog and the remainder is given as a basal infusion.
                                    <span class="Italics">,
                                        <a href="#i4i_section_id_5176eac9-1bc2-43f4-b02c-2bb6ddb9cabc">Warnings and Precautions (5.8,</a><a href="#i4i_section_id_f2c5cc99-438c-4ab0-997f-a65808e7f3e7">5.9)</a><a href="#i4i_storage_id_af41a3f6-59d7-4db1-a09e-3b81ed0d89f3">How Supplied/Storage and Handling (16.2)</a></span><span class="Bold">Change the NovoLog in the reservoir at least every 6 days, change the infusion sets and the infusion set insertion site at least every 3 days.</span></p>
<p>The following insulin pumps† have been used in NovoLog clinical or in vitro studies conducted by Novo Nordisk, the manufacturer of NovoLog:</p>
<dl>
<dt>•</dt>
<dd>Medtronic Paradigm® 512 and 712
                                        </dd>
<dt>•</dt>
<dd>MiniMed 508
                                        </dd>
<dt>•</dt>
<dd>Disetronic® D-TRON® and H-TRON®
                                        </dd>
</dl>
<p>Before using a different insulin pump with NovoLog, read the pump label to make sure the pump has been evaluated with NovoLog.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_422c6521-2edd-40c4-abb3-25735c59d3d8"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Intravenous Use</h2>
<p class="First">NovoLog can be administered intravenously under medical supervision for glycemic control with close monitoring of blood glucose and potassium levels to avoid <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> [ ]. For intravenous use, NovoLog should be used at concentrations from 0.05 U/mL to 1.0 U/mL insulin aspart in infusion systems using polypropylene infusion bags. NovoLog has been shown to be stable in infusion fluids such as 0.9% sodium chloride.
                                    <span class="Italics">see ,
                                        <a href="#i4i_section_id_f2c5cc99-438c-4ab0-997f-a65808e7f3e7">Warnings and Precautions (5)</a><a href="#i4i_how_supplied_id_fd0dcf7e-b877-436d-9d3f-f9023f53f1f0">How Supplied/Storage and Handling (16.2)</a></span></p>
<p>Inspect NovoLog for particulate matter and discoloration prior to parenteral administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_dcf06632-114f-4ddd-bf50-e92db92f8b0a"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">NovoLog is available in the following package sizes: each presentation contains 100 units of insulin aspart per mL (U-100).</p>
<dl>
<dt>•</dt>
<dd>10 mL vials
                                </dd>
<dt>•</dt>
<dd>3 mL PenFill cartridges for the 3 mL PenFill cartridge delivery device (with or without the addition of a NovoPen 3 PenMate ) with  NovoFine disposable needles
                                <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>3 mL NovoLog FlexPen
                                </dd>
<dt>•</dt>
<dd>3 mL NovoLog FlexTouch
                                </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_01bdca45-e233-4653-8c55-7a34ea928495"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">NovoLog is contraindicated</p>
<dl>
<dt>•</dt>
<dd>during episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>
                                </dd>
<dt>•</dt>
<dd>in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to NovoLog or one of its excipients.
                                </dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_4bc7c883-0765-44cd-8028-c744ee1c4853"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_09c5c9cf-72ff-45a7-ade3-91bc977b5a4e"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Administration</h2>
<p class="First">NovoLog has a more rapid onset of action and a shorter duration of activity than regular human insulin. An injection of NovoLog should immediately be followed by a meal within 5-10 minutes. Because of NovoLog’s short duration of action, a longer acting insulin should also be used in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and may also be needed in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Glucose monitoring is recommended for all patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and is particularly important for patients using external pump infusion therapy.</p>
<p>Any change of insulin dose should be made cautiously and only under medical supervision. Changing from one insulin product to another or changing the insulin strength may result in the need for a change in dosage. As with all insulin preparations, the time course of NovoLog action may vary in different individuals or at different times in the same individual and is dependent on many conditions, including the site of injection, local blood supply, temperature, and physical activity. Patients who change their level of physical activity or meal plan may require adjustment of insulin dosages. Insulin requirements may be altered during illness, <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">emotional disturbances</span>, or other stresses.</p>
<p>Patients using continuous subcutaneous insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.</p>
<p><span class="Bold">Needles, NovoLog FlexPen and NovoLog FlexTouch must not be shared.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a99b82e-9709-4c93-acf8-0454b9e4464d"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> is the most common adverse effect of all insulin therapies, including NovoLog. Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may lead to <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and/or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and may result in temporary or permanent impairment of brain function or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> requiring the assistance of another person and/or parenteral glucose infusion or glucagon administration has been observed in clinical trials with insulin, including trials with NovoLog.</p>
<p>The timing of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> usually reflects the time-action profile of the administered insulin formulations [ ]. Other factors such as changes in food intake (e.g., amount of food or timing of meals), injection site, exercise, and concomitant medications may also alter the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> [ ]. As with all insulins, use caution in patients with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> unawareness and in patients who may be predisposed to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (e.g., patients who are fasting or have erratic food intake). The patient’s ability to concentrate and react may be impaired as a result of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery.
                                    <span class="Italics">see
                                        <a href="#i4i_clinical_pharmacology_id_737059e5-a212-411c-b08c-bd752f10e178">Clinical Pharmacology (12)</a></span><span class="Italics">see
                                        <a href="#i4i_interactions_id_ddfdb67c-93b9-4d18-8d10-f67a37844f7c">Drug Interactions (7)</a></span></p>
<p>Rapid changes in serum glucose levels may induce symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in persons with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, regardless of the glucose value. Early warning symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be different or less pronounced under certain conditions, such as longstanding <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, diabetic nerve disease, use of medications such as beta-blockers, or intensified <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> control [ ]. These situations may result in severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (and, possibly, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>) prior to the patient’s awareness of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Intravenously administered insulin has a more rapid onset of action than subcutaneously administered insulin, requiring more close monitoring for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.
                                    <span class="Italics">see
                                        <a href="#i4i_interactions_id_ddfdb67c-93b9-4d18-8d10-f67a37844f7c">Drug Interactions (7)</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_88b35ef8-a0b4-4d7d-bbb8-4e27079c62d1"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></h2>
<p class="First">All insulin products, including NovoLog, cause a shift in potassium from the extracellular to intracellular space, possibly leading to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> that, if left untreated, may cause <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Use caution in patients who may be at risk for <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations, and patients receiving intravenously administered insulin).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c6ad6e0-abec-45fb-bb1a-1cfe895862c4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">As with other insulins, the dose requirements for NovoLog may be reduced in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [ ].
                                    <span class="Italics">see
                                        <a href="#i4i_pharmacokinetics_id_48189ee4-6cdf-4007-9538-bf0142b65804">Clinical Pharmacology (12.3)</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a2a42026-9e15-4c53-886d-dc798f2e7860"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">As with other insulins, the dose requirements for NovoLog may be reduced in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [ ].
                                    <span class="Italics">see
                                        <a href="#i4i_pharmacokinetics_id_48189ee4-6cdf-4007-9538-bf0142b65804">Clinical Pharmacology (12.3)</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_782f84f8-a53e-48d2-9fe1-dcc1bab34ab0"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">- As with other insulin therapy, patients may experience <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> at the site of NovoLog injection. These reactions usually resolve in a few days to a few weeks, but in some occasions, may require discontinuation of NovoLog. In some instances, these reactions may be related to factors other than insulin, such as irritants in a skin cleansing agent or poor injection technique. Localized reactions and generalized <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> have been reported with injected metacresol, which is an excipient in NovoLog.
                                    <span class="Italics">Local Reactions</span></p>
<p>- Severe, life-threatening, generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, may occur with any insulin product, including NovoLog. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> with NovoLog have been reported post-approval. Generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to insulin may also cause whole body <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (including <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, or <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>. In controlled clinical trials, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> were reported in 3 of 735 patients (0.4%) treated with regular human insulin and 10 of 1394 patients (0.7%) treated with NovoLog. In controlled and uncontrolled clinical trials, 3 of 2341 (0.1%) NovoLog-treated patients discontinued due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.
                                    <span class="Italics">Systemic Reactions</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75b84e5e-f957-43e9-9cdc-9d8425927a3f"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Antibody Production</h2>
<p class="First">Increases in anti-insulin antibody titers that react with both human insulin and insulin aspart have been observed in patients treated with NovoLog. Increases in anti-insulin antibodies are observed more frequently with NovoLog than with regular human insulin. Data from a 12-month controlled trial in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> suggest that the increase in these antibodies is transient, and the differences in antibody levels between the regular human insulin and insulin aspart treatment groups observed at 3 and 6 months were no longer evident at 12 months. In this study these antibodies did not appear to cause deterioration in glycemic control or necessitate increases in insulin dose.</p>
<p>In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency towards <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> or <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5176eac9-1bc2-43f4-b02c-2bb6ddb9cabc"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Mixing of Insulins</h2>
<dl>
<dt>•</dt>
<dd>Mixing NovoLog with NPH human insulin immediately before injection attenuates the peak concentration of NovoLog, without significantly affecting the time to peak concentration or total bioavailability of NovoLog. If NovoLog is mixed with NPH human insulin, NovoLog should be drawn into the syringe first, and the mixture should be injected immediately after mixing.
                                        </dd>
<dt>•</dt>
<dd>The efficacy and safety of mixing NovoLog with insulin preparations produced by other manufacturers have not been studied.
                                        </dd>
<dt>•</dt>
<dd>Insulin mixtures should not be administered intravenously.
                                        </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f2c5cc99-438c-4ab0-997f-a65808e7f3e7"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Continuous Subcutaneous Insulin Infusion by External Pump</h2>
<p class="First">When using NovoLog in an external insulin pump, the NovoLog-specific information should be followed (e.g., in-use time, frequency of changing infusion sets) because NovoLog-specific information may differ from general pump manual instructions.
                                    <span class="Bold">When used in an external subcutaneous insulin infusion pump, NovoLog should not be mixed with any other insulin or diluent.</span></p>
<p>Pump or infusion set malfunctions or insulin degradation can lead to a rapid onset of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="4101761" conceptname="Ketosis">ketosis</span> because of the small subcutaneous depot of insulin. This is especially pertinent for rapid-acting insulin analogs that are more rapidly absorbed through skin and have a shorter duration of action. Prompt identification and correction of the cause of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> or <span class="product-label-link" type="condition" conceptid="4101761" conceptname="Ketosis">ketosis</span> is necessary. Interim therapy with subcutaneous injection may be required [ ].
                                    <span class="Italics">see , , , and
                                        <a href="#i4i_section_id_a770e1c4-6919-4dd1-80c9-af7d306920bb">Dosage and Administration (2.3)</a><a href="#i4i_section_id_5176eac9-1bc2-43f4-b02c-2bb6ddb9cabc">Warnings and Precautions (5.8, 5.9)</a><a href="#i4i_storage_id_af41a3f6-59d7-4db1-a09e-3b81ed0d89f3">How Supplied/Storage and Handling (16.2)</a><a href="#i4i_section_id_14ea1a11-7dc4-4eec-bc4c-532bc90c5d4d">Patient Counseling Information (17.2)</a></span></p>
<p>NovoLog should not be exposed to temperatures greater than 37°C (98.6°F). [ ].
                                    <span class="Bold">NovoLog that will be used in a pump should not be mixed with other insulin or with a diluent</span><span class="Italics">see , , and
                                        <a href="#i4i_section_id_a770e1c4-6919-4dd1-80c9-af7d306920bb">Dosage and Administration (2.3)</a><a href="#i4i_section_id_5176eac9-1bc2-43f4-b02c-2bb6ddb9cabc">Warnings and Precautions (5.8,</a><a href="#i4i_section_id_f2c5cc99-438c-4ab0-997f-a65808e7f3e7">5.9),</a><a href="#i4i_storage_id_af41a3f6-59d7-4db1-a09e-3b81ed0d89f3">How Supplied/Storage and Handling (16.2)</a><a href="#i4i_section_id_14ea1a11-7dc4-4eec-bc4c-532bc90c5d4d">Patient Counseling Information (17.2)</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4bef2190-6df9-4c0c-b9d7-83c494519310"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with concomitant use of PPAR-gamma agonists</h2>
<p class="First">Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, particularly when used in combination with insulin. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> may lead to or exacerbate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Patients treated with insulin, including NovoLog, and a PPAR-gamma agonist should be observed for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_178c7422-f521-4313-8741-676470787aca"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold"><span class="Italics">Clinical Trial Experience</span></span></p>
<p>Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.</p>
<dl>
<dt>•</dt>
<dd><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></span></dd>
</dl>
<p><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> is the most commonly observed adverse reaction in patients using insulin, including NovoLog [ ].
                            <span class="Italics">see
                                <a href="#i4i_warnings_precautions_id_4bc7c883-0765-44cd-8028-c744ee1c4853">Warnings and Precautions (5)</a></span></p>
<dl>
<dt>•</dt>
<dd><span class="Italics"><span class="Underline">Insulin initiation and glucose control intensification</span></span></dd>
</dl>
<p>Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic <span class="product-label-link" type="condition" conceptid="380727" conceptname="Transient refractive change">refraction disorder</span>, worsening of <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">diabetic retinopathy</span>, and acute painful <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. However, long-term glycemic control decreases the risk of <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">diabetic retinopathy</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>.</p>
<dl>
<dt>•</dt>
<dd><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">Lipodystrophy</span></span></span></dd>
</dl>
<p>Long-term use of insulin, including NovoLog, can cause <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> at the site of repeated insulin injections or infusion. <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">Lipodystrophy</span> includes <span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">lipohypertrophy</span> (thickening of adipose tissue) and <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span> (thinning of adipose tissue), and may affect insulin absorption. Rotate insulin injection or infusion sites within the same region to reduce the risk of <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>.</p>
<dl>
<dt>•</dt>
<dd><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></span></span></dd>
</dl>
<p><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> can occur with some insulin therapies, including NovoLog, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.</p>
<dl>
<dt>•</dt>
<dd><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></span></span></dd>
</dl>
<p>Insulin may cause <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, particularly if previously poor metabolic control is improved by intensified insulin therapy.</p>
<dl>
<dt>•</dt>
<dd><span class="Italics"><span class="Underline">Frequencies of adverse drug reactions</span></span></dd>
</dl>
<p>The frequencies of adverse drug reactions during NovoLog clinical trials in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus are listed in the tables below.</p>
<a name="_Refid_bb3112c9-04a8-4972-bb0f-d61b3f4b0"></a><table>
<caption><span>Table 1: Treatment-Emergent Adverse Events in Patients with Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus (Adverse events with frequency ≥ 5% and occurring more frequently with NovoLog compared to human regular insulin are listed)</span></caption>
<col width="36%">
<col width="18%">
<col width="13%">
<col width="13%">
<col width="21%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> is defined as an episode of blood glucose concentration &lt;45 mg/dL, with or without symptoms. See Section 14 for the incidence of serious <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in the individual clinical trials.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">NovoLog + NPH</span></p>
<p><span class="Bold">N= 596</span></p>
</td>
<td class="Botrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">Human Regular Insulin + NPH</span></p>
<p><span class="Bold">N= 286</span></p>
</td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Preferred Term</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">(%)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(%)</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>
                                            <a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">448</p></td>
<td class="Botrule Rrule" align="center"><p class="First">75%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">205</p></td>
<td class="Botrule" align="center"><p class="First">72%</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">70</p></td>
<td class="Botrule Rrule" align="center"><p class="First">12%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">28</p></td>
<td class="Botrule" align="center"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Injury accidental</p></td>
<td class="Botrule Rrule" align="center"><p class="First">65</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">29</p></td>
<td class="Botrule" align="center"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">43</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule" align="center"><p class="First">5%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">28</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule" align="center"><p class="First">3%</p></td>
</tr>
</tbody>
</table>
<a name="_RefID0EL6AE"></a><table>
<caption><span>Table 2: Treatment-Emergent Adverse Events in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus (except for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, adverse events with frequency ≥ 5% and occurring more frequently with NovoLog compared to human regular insulin are listed)</span></caption>
<col width="36%">
<col width="18%">
<col width="13%">
<col width="15%">
<col width="19%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> is defined as an episode of blood glucose concentration &lt;45 mg/dL, with or without symptoms. See Section 14 for the incidence of serious <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in the individual clinical trials.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">NovoLog + NPH</span></p>
<p><span class="Bold">N= 91</span></p>
</td>
<td class="Botrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">Human Regular Insulin + NPH</span></p>
<p><span class="Bold">N= 91</span></p>
</td>
</tr>
<tr>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">(%)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(%)</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>
                                            <a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">25</p></td>
<td class="Botrule Rrule" align="center"><p class="First">27%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">33</p></td>
<td class="Botrule" align="center"><p class="First">36%</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">Hyporeflexia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule" align="center"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">10%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule" align="center"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">Sensory disturbance</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">9%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule" align="center"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule" align="center"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule" align="center"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule" align="center"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin disorder</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule" align="center"><p class="First">1%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule" align="center"><p class="First">1%</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Postmarketing Data</span></span></p>
<p>The following additional adverse reactions have been identified during postapproval use of NovoLog. Because these adverse reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency. Medication errors in which other insulins have been accidentally substituted for NovoLog have been identified during postapproval use [ ].
                            <span class="Italics">see
                                <a href="#i4i_info_patients_id_74a7af07-8011-4ddf-9fbc-46a57c903e96">Patient Counseling Information (17)</a></span></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_ddfdb67c-93b9-4d18-8d10-f67a37844f7c"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.</p>
<dl>
<dt>•</dt>
<dd>The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>: oral antidiabetic products, pramlintide, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
                                </dd>
<dt>•</dt>
<dd>The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), atypical antipsychotics.
                                </dd>
<dt>•</dt>
<dd>Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
                                </dd>
<dt>•</dt>
<dd>Pentamidine may cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, which may sometimes be followed by <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.
                                </dd>
<dt>•</dt>
<dd>The signs of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be reduced or absent in patients taking sympatholytic products such as beta-blockers, clonidine, guanethidine, and reserpine.
                                </dd>
</dl>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_a652c952-9993-4332-aeb5-0d5abd2a5a0a"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_0af73a5a-54a1-4056-bd48-b24c369c7257"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B. All pregnancies have a background risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and may be decreased with good metabolic control. It is essential for patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or history of <span class="product-label-link" type="condition" conceptid="4024659" conceptname="Gestational diabetes mellitus">gestational diabetes</span> to maintain good metabolic control before conception and throughout pregnancy. Insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. Careful monitoring of glucose control is essential in these patients. Therefore, female patients should be advised to tell their physician if they intend to become, or if they become pregnant while taking NovoLog.</p>
<p>An open-label, randomized study compared the safety and efficacy of NovoLog (n=157) versus regular human insulin (n=165) in 322 pregnant women with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Two-thirds of the enrolled patients were already pregnant when they entered the study. Because only one-third of the patients enrolled before conception, the study was not large enough to evaluate the risk of congenital malformations. Both groups achieved a mean HbA of ~ 6% during pregnancy, and there was no significant difference in the incidence of maternal <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.
                                    <span class="Sub">1c</span></p>
<p>Subcutaneous reproduction and teratology studies have been performed with NovoLog and regular human insulin in rats and rabbits. In these studies, NovoLog was given to female rats before mating, during mating, and throughout pregnancy, and to rabbits during organogenesis. The effects of NovoLog did not differ from those observed with subcutaneous regular human insulin. NovoLog, like human insulin, caused pre- and post-implantation losses and visceral/skeletal abnormalities in rats at a dose of 200 U/kg/day (approximately 32 times the human subcutaneous dose of 1.0 U/kg/day, based on U/body surface area) and in rabbits at a dose of 10 U/kg/day (approximately three times the human subcutaneous dose of 1.0 U/kg/day, based on U/body surface area). The effects are probably secondary to maternal <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> at high doses. No significant effects were observed in rats at a dose of 50 U/kg/day and in rabbits at a dose of 3 U/kg/day. These doses are approximately 8 times the human subcutaneous dose of 1.0 U/kg/day for rats and equal to the human subcutaneous dose of 1.0 U/kg/day for rabbits, based on U/body surface area.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_f26b80b5-282a-4950-b66b-8a7aa10f5e4c"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is unknown whether insulin aspart is excreted in human milk. Use of NovoLog is compatible with breastfeeding, but women with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who are lactating may require adjustments of their insulin doses.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_175e45af-b079-495a-bb10-1ca04d00b1da"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">NovoLog is approved for use in children for subcutaneous daily injections and for subcutaneous continuous infusion by external insulin pump. NovoLog has not been studied in pediatric patients younger than 2 years of age. NovoLog has not been studied in pediatric patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Please see   for summaries of clinical studies.
                                    <span class="Italics">Section 14
                                        <span class="Bold"><a href="#i4i_clinical_studies_id_d26e2bbe-251b-4603-ada9-db522d2c2ac2">CLINICAL STUDIES</a></span></span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_0d66f096-5015-44c7-b079-45e787167d4f"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of patients (n= 1,375) treated with NovoLog in 3 controlled clinical studies, 2.6% (n=36) were 65 years of age or over. One-half of these patients had type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (18/1285) and the other half had type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (18/90). The HbA response to NovoLog, as compared to human insulin, did not differ by age, particularly in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Additional studies in larger populations of patients 65 years of age or over are needed to permit conclusions regarding the safety of NovoLog in elderly compared to younger patients. Pharmacokinetic/pharmacodynamic studies to assess the effect of age on the onset of NovoLog action have not been performed.
                                    <span class="Sub">1c</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_d2271851-8e42-431e-b957-6a33c626ee81"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Excess insulin administration may cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and, particularly when given intravenously, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Mild episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise, may be needed. More severe episodes with <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may recur after apparent clinical recovery. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> must be corrected appropriately.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_7f0019da-eddb-4168-807a-44b5de715998"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">NovoLog (insulin aspart [rDNA origin] injection) is a rapid-acting human insulin analog used to lower blood glucose. NovoLog is homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing (baker's yeast). Insulin aspart has the empirical formula C H N 0 S and a molecular weight of 5825.8.
                            <span class="Italics">Saccharomyces cerevisiae</span><span class="Sub">256</span><span class="Sub">381</span><span class="Sub">65</span><span class="Sub">79</span><span class="Sub">6</span></p>
<div class="Figure">
<a name="id1124"></a><img alt="Fig. 1 - Structural Formula of Insulin Aspart" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-01.jpg"><p class="MultiMediaCaption">Figure 1. Structural formula of insulin aspart.</p>
</div>
<p>NovoLog is a sterile, aqueous, clear, and colorless solution, that contains insulin aspart 100 Units/mL, glycerin 16 mg/mL, phenol 1.50 mg/mL, metacresol 1.72 mg/mL, zinc 19.6 mcg/mL, disodium hydrogen phosphate dihydrate 1.25 mg/mL, sodium chloride 0.58 mg/mL and water for injection. NovoLog has a pH of 7.2-7.6. Hydrochloric acid 10% and/or sodium hydroxide 10% may be added to adjust pH.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_737059e5-a212-411c-b08c-bd752f10e178"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_7281a8c0-8b0a-4234-8251-f1c9f6275fd1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The primary activity of NovoLog is the regulation of glucose metabolism. Insulins, including NovoLog, bind to the insulin receptors on muscle and fat cells and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_c2ce926d-4148-4445-a300-fa67506910f8"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Studies in normal volunteers and patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> demonstrated that subcutaneous administration of NovoLog has a more rapid onset of action than regular human insulin.</p>
<p>In a study in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (n=22), the maximum glucose-lowering effect of NovoLog occurred between 1 and 3 hours after subcutaneous injection (see Figure 2). The duration of action for NovoLog is 3 to 5 hours. The time course of action of insulin and insulin analogs such as NovoLog may vary considerably in different individuals or within the same individual. The parameters of NovoLog activity (time of onset, peak time and duration) as designated in Figure 2 should be considered only as general guidelines. The rate of insulin absorption and onset of activity is affected by the site of injection, exercise, and other variables [ ].
                                    <span class="Italics">see
                                        <a href="#i4i_section_id_09c5c9cf-72ff-45a7-ade3-91bc977b5a4e">Warnings and Precautions (5.1)</a></span></p>
<div class="Figure">
<a name="id1155"></a><img alt="Fig. 2 - Pharmacodynamics Graph showing Maximum Glucose-Lowering Effect of NovoLog" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-02.jpg"><p class="MultiMediaCaption">Figure 2. Serial mean serum glucose collected up to 6 hours following a single pre-meal dose of NovoLog (solid curve) or regular human insulin (hatched curve) injected immediately before a meal in 22 patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</p>
</div>
<p>A double-blind, randomized, two-way cross-over study in 16 patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> demonstrated that intravenous infusion of NovoLog resulted in a blood glucose profile that was similar to that after intravenous infusion with regular human insulin. NovoLog or human insulin was infused until the patient’s blood glucose decreased to 36 mg/dL, or until the patient demonstrated signs of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (rise in heart rate and onset of <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>), defined as the time of autonomic reaction (R) (see Figure 3).</p>
<div class="Figure">
<a name="id1158"></a><img alt="Fig. 3 - Pharmacodynamics Graph - Time of Autonomic Reaction" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-03.jpg"><p class="MultiMediaCaption">Figure 3. Mean blood glucose profiles following intravenous infusion of NovoLog (hatched curve) and regular human insulin (solid curve) in 16 patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. R represents the time of autonomic reaction.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_48189ee4-6cdf-4007-9538-bf0142b65804"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The single substitution of the amino acid proline with aspartic acid at position B28 in NovoLog reduces the molecule's tendency to form hexamers as observed with regular human insulin. NovoLog is, therefore, more rapidly absorbed after subcutaneous injection compared to regular human insulin.</p>
<p>In a randomized, double-blind, crossover study 17 healthy Caucasian male subjects between 18 and 40 years of age received an intravenous infusion of either NovoLog or regular human insulin at 1.5 mU/kg/min for 120 minutes. The mean insulin clearance was similar for the two groups with mean values of 1.2 l/h/kg for the NovoLog group and 1.2 l/h/kg for the regular human insulin group.</p>
<p>- NovoLog has a faster absorption, a faster onset of action, and a shorter duration of action than regular human insulin after subcutaneous injection (see Figure 2 and Figure 4). The relative bioavailability of NovoLog compared to regular human insulin indicates that the two insulins are absorbed to a similar extent.
                                    <span class="Italics">Bioavailability and Absorption</span></p>
<div class="Figure">
<a name="id1171"></a><img alt="Fig. 4 - Pharmacokinetics Graph showing Bioavailability and Absorption of NovoLog" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-04.jpg"><p class="MultiMediaCaption">Figure 4. Serial mean serum free insulin concentration collected up to 6 hours following a single pre-meal dose of NovoLog (solid curve) or regular human insulin (hatched curve) injected immediately before a meal in 22 patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</p>
</div>
<p>In studies in healthy volunteers (total n=107) and patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (total n=40), NovoLog consistently reached peak serum concentrations approximately twice as fast as regular human insulin. The median time to maximum concentration in these trials was 40 to 50 minutes for NovoLog versus 80 to 120 minutes for regular human insulin. In a clinical trial in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, NovoLog and regular human insulin, both administered subcutaneously at a dose of 0.15 U/kg body weight, reached mean maximum concentrations of 82 and 36 mU/L respectively. Pharmacokinetic/pharmacodynamic characteristics of insulin aspart have not been established in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.
                                    <span class="Italics">,</span></p>
<p>The intra-individual variability in time to maximum serum insulin concentration for healthy male volunteers was significantly less for NovoLog than for regular human insulin. The clinical significance of this observation has not been established.</p>
<p>In a clinical study in healthy non-obese subjects, the pharmacokinetic differences between NovoLog and regular human insulin described above, were observed independent of the site of injection (abdomen, thigh, or upper arm).</p>
<p>- NovoLog has low binding to plasma proteins (&lt;10%), similar to that seen with regular human insulin. After subcutaneous administration in normal male volunteers (n=24), NovoLog was more rapidly eliminated than regular human insulin with an average apparent half-life of 81 minutes compared to 141 minutes for regular human insulin.
                                    <span class="Italics">Distribution and Elimination</span></p>
<p><span class="Bold">Specific Populations</span></p>
<p>- The pharmacokinetic and pharmacodynamic properties of NovoLog and regular human insulin were evaluated in a single dose study in 18 children (6-12 years, n=9) and adolescents (13-17 years [Tanner grade 2], n=9) with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The relative differences in pharmacokinetics and pharmacodynamics in children and adolescents with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> between NovoLog and regular human insulin were similar to those in healthy adult subjects and adults with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.
                                    <span class="Italics">Children and Adolescents</span><span class="Underline">&gt;</span></p>
<p>- In healthy volunteers, no difference in insulin aspart levels was seen between men and women when body weight differences were taken into account. There was no significant difference in efficacy noted (as assessed by HbA ) between genders in a trial in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.
                                    <span class="Italics">Gender</span><span class="Sub">lc</span></p>
<p>- A single subcutaneous dose of 0.1 U/kg NovoLog was administered in a study of 23 patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and a wide range of body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI, 22-39 kg/m ). The pharmacokinetic parameters, AUC and C , of NovoLog were generally unaffected by BMI in the different groups – BMI 19-23 kg/m (N=4); BMI 23-27 kg/m (N=7); BMI 27-32 kg/m (N=6) and BMI &gt;32 kg/m (N=6). Clearance of NovoLog was reduced by 28% in patients with BMI &gt;32 kg/m compared to patients with BMI &lt;23 kg/m .
                                    <span class="Italics"><span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span></span><span class="Sup">2</span><span class="Sub">max</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span></p>
<p>- Some studies with human insulin have shown increased circulating levels of insulin in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. A single subcutaneous dose of 0.08 U/kg NovoLog was administered in a study to subjects with either normal (N=6) creatinine clearance (CLcr) (&gt; 80 ml/min) or mild (N=7; CLcr = 50-80 ml/min), moderate (N=3; CLcr = 30-50 ml/min) or severe (but not requiring hemodialysis) (N=2; CLcr = &lt;30 ml/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In this small study, there was no apparent effect of creatinine clearance values on AUC and C of NovoLog. Careful glucose monitoring and dose adjustments of insulin, including NovoLog, may be necessary in patients with renal dysfunction [ ].
                                    <span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><span class="Sub">max</span><span class="Italics">see
                                        <a href="#i4i_section_id_4c6ad6e0-abec-45fb-bb1a-1cfe895862c4">Warnings and Precautions (5.4)</a></span></p>
<p>- Some studies with human insulin have shown increased circulating levels of insulin in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. A single subcutaneous dose of 0.06 U/kg NovoLog was administered in an open-label, single-dose study of 24 subjects (N=6/group) with different degree of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (mild, moderate and severe) having Child-Pugh Scores ranging from 0 (healthy volunteers) to 12 (severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>). In this small study, there was no correlation between the degree of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> and any NovoLog pharmacokinetic parameter. Careful glucose monitoring and dose adjustments of insulin, including NovoLog, may be necessary in patients with hepatic dysfunction [ ].
                                    <span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span><span class="Italics">see
                                        <a href="#i4i_section_id_a2a42026-9e15-4c53-886d-dc798f2e7860">Warnings and Precautions (5.5)</a></span></p>
<p>The effect of age, ethnic origin, pregnancy and smoking on the pharmacokinetics and pharmacodynamics of NovoLog has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_17697809-54e9-4549-b421-d2eab6988263"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_98d61bfd-d08f-4ac4-8239-0259c677fa34"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Standard 2-year carcinogenicity studies in animals have not been performed to evaluate the carcinogenic potential of NovoLog. In 52-week studies, Sprague-Dawley rats were dosed subcutaneously with NovoLog at 10, 50, and 200 U/kg/day (approximately 2, 8, and 32 times the human subcutaneous dose of 1.0 U/kg/day, based on U/body surface area, respectively). At a dose of 200 U/kg/day, NovoLog increased the incidence of mammary gland tumors in females when compared to untreated controls. The incidence of mammary tumors for NovoLog was not significantly different than for regular human insulin. The relevance of these findings to humans is not known. NovoLog was not genotoxic in the following tests: Ames test, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell forward gene mutation test, human peripheral blood lymphocyte chromosome aberration test, micronucleus test in mice, and in UDS test in rat liver hepatocytes. In fertility studies in male and female rats, at subcutaneous doses up to 200 U/kg/day (approximately 32 times the human subcutaneous dose, based on U/body surface area), no direct adverse effects on male and female fertility, or general reproductive performance of animals was observed.
                                    <span class="Italics">in vivo</span><span class="Italics">ex vivo</span></p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_09df25f0-a3f8-4398-9415-b1e4e25ada9b"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">In standard biological assays in mice and rabbits, one unit of NovoLog has the same glucose-lowering effect as one unit of regular human insulin. In humans, the effect of NovoLog is more rapid in onset and of shorter duration, compared to regular human insulin, due to its faster absorption after subcutaneous injection (see Figure 2 and Figure 4).
                                    <span class="Italics">Section 12
                                        <a href="#i4i_clinical_pharmacology_id_737059e5-a212-411c-b08c-bd752f10e178">CLINICAL PHARMACOLOGY</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_d26e2bbe-251b-4603-ada9-db522d2c2ac2"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_74e1d412-6e30-44e5-b8ef-df8235fea69d"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Subcutaneous Daily Injections</h2>
<p class="First">Two six-month, open-label, active-controlled studies were conducted to compare the safety and efficacy of NovoLog to Novolin R in adult patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Because the two study designs and results were similar, data are shown for only one study (see ). NovoLog was administered by subcutaneous injection immediately prior to meals and regular human insulin was administered by subcutaneous injection 30 minutes before meals. NPH insulin was administered as the basal insulin in either single or divided daily doses. Changes in HbA and the incidence rates of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (as determined from the number of events requiring intervention from a third party) were comparable for the two treatment regimens in this study ( ) as well as in the other clinical studies that are cited in this section. <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic ketoacidosis</span> was not reported in any of the adult studies in either treatment group.
                                    <a href="#_Refid_d161d700-dbe2-4be9-b218-0b25d1467">Table 3</a><span class="Sub">1c</span><a href="#_Refid_d161d700-dbe2-4be9-b218-0b25d1467">Table 3</a></p>
<a name="_Refid_d161d700-dbe2-4be9-b218-0b25d1467"></a><table>
<caption><span>Table 3. Subcutaneous NovoLog Administration in Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (24 weeks; n=882)</span></caption>
<col width="58%">
<col width="20%">
<col width="22%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Values are Mean ± SD</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> refers to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> associated with central nervous system symptoms and requiring the intervention of another person or hospitalization.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">NovoLog + NPH</p></td>
<td class="Botrule Toprule" align="center"><p class="First">Novolin R + NPH</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">N</p></td>
<td class="Botrule Rrule" align="center"><p class="First">596</p></td>
<td class="Botrule" align="center"><p class="First">286</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline HbA (%)
                                                    <span class="Sub">1c</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">7.9 ±1.1</p></td>
<td class="Botrule" align="center"><p class="First">8.0 ± 1.2</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Change from Baseline HbA (%)
                                                    <span class="Sub">1c</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">-0.1 ± 0.8</p></td>
<td class="Botrule" align="center"><p class="First">0.0 ± 0.8</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Treatment Difference in HbA Mean (95% confidence interval)
                                                    <span class="Sub">1c,</span></p></td>
<td class="Botrule" align="center" colspan="2"><p class="First">-0.2 (-0.3, -0.1)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline insulin dose (IU/kg/24 hours)
                                                    <a href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 ± 0.2</p></td>
<td class="Botrule" align="center"><p class="First">0.7 ± 0.2</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">End-of-Study insulin dose (IU/kg/24 hours)
                                                    <a href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 ± 0.2</p></td>
<td class="Botrule" align="center"><p class="First">0.7 ± 0.2</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Patients with severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (n, %)
                                                    <a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">104 (17%)</p></td>
<td class="Botrule" align="center"><p class="First">54 (19%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule">
<p class="First">Baseline body weight (kg)
                                                    <a href="#footnote-3" class="Sup">*</a></p>
<p>Weight Change from baseline (kg)
                                                    <a href="#footnote-3" class="Sup">*</a></p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">75.3 ± 14.5</p>
<p>0.5 ± 3.3</p>
</td>
<td class="Botrule" align="center">
<p class="First">75.9 ± 13.1</p>
<p>0.9 ± 2.9</p>
</td>
</tr>
</tbody>
</table>
<p>A 24-week, parallel-group study of children and adolescents with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (n = 283) aged 6 to 18 years compared two subcutaneous multiple-dose treatment regimens: NovoLog (n = 187) or Novolin R (n = 96). NPH insulin was administered as the basal insulin. NovoLog achieved glycemic control comparable to Novolin R, as measured by change in HbA ( ) and both treatment groups had a comparable incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Subcutaneous administration of NovoLog and regular human insulin have also been compared in children with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (n=26) aged 2 to 6 years with similar effects on HbA and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.
                                    <span class="Sub">1c</span><a href="#_Refid_33d5f81e-2203-4e1e-8ef3-0c2f06cfa">Table 4</a><span class="Sub">1c</span></p>
<a name="_Refid_33d5f81e-2203-4e1e-8ef3-0c2f06cfa"></a><table>
<caption><span>Table 4. Pediatric Subcutaneous Administration of NovoLog in Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (24 weeks; n=283)</span></caption>
<col width="58%">
<col width="21%">
<col width="21%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Values are Mean ± SD</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> refers to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> associated with central nervous system symptoms and requiring the intervention of another person or hospitalization.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">NovoLog + NPH</p></td>
<td class="Botrule Toprule" align="center"><p class="First">Novolin R + NPH</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">N</p></td>
<td class="Botrule Rrule" align="center"><p class="First">187</p></td>
<td class="Botrule" align="center"><p class="First">96</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline HbA (%)
                                                    <span class="Sub">1c</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.3 ± 1.2</p></td>
<td class="Botrule" align="center"><p class="First">8.3 ± 1.3</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Change from Baseline HbA (%)
                                                    <span class="Sub">1c</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.1± 1.0</p></td>
<td class="Botrule" align="center"><p class="First">0.1± 1.1</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Treatment Difference in HbA Mean (95% confidence interval)
                                                    <span class="Sub">1c,</span></p></td>
<td class="Botrule" align="center" colspan="2"><p class="First">0.1 (-0.5, 0.1)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline insulin dose (IU/kg/24 hours)
                                                    <a href="#footnote-5" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.4 ± 0.2</p></td>
<td class="Botrule" align="center"><p class="First">0.6 ± 0.2</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">End-of-Study insulin dose (IU/kg/24 hours)
                                                    <a href="#footnote-5" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.4 ± 0.2</p></td>
<td class="Botrule" align="center"><p class="First">0.7 ± 0.2</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Patients with severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (n, %)
                                                    <a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">11 (6%)</p></td>
<td class="Botrule" align="center"><p class="First">9 (9%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic ketoacidosis</span> (n, %)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">10 (5%)</p></td>
<td class="Botrule" align="center"><p class="First">2 (2%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule">
<p class="First">Baseline body weight (kg)
                                                    <a href="#footnote-5" class="Sup">*</a></p>
<p>Weight Change from baseline (kg)
                                                    <a href="#footnote-5" class="Sup">*</a></p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">50.6 ± 19.6</p>
<p>2.7 ± 3.5</p>
</td>
<td class="Botrule" align="center">
<p class="First">48.7 ± 15.8</p>
<p>2.4 ± 2.6</p>
</td>
</tr>
</tbody>
</table>
<p>One six-month, open-label, active-controlled study was conducted to compare the safety and efficacy of NovoLog to Novolin R in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> ( ). NovoLog was administered by subcutaneous injection immediately prior to meals and regular human insulin was administered by subcutaneous injection 30 minutes before meals. NPH insulin was administered as the basal insulin in either single or divided daily doses. Changes in HbA and the rates of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (as determined from the number of events requiring intervention from a third party) were comparable for the two treatment regimens.
                                    <a href="#_Refid_1b921a57-712b-423b-9b54-cf24bcd4e">Table 5</a><span class="Sub">lc</span></p>
<a name="_Refid_1b921a57-712b-423b-9b54-cf24bcd4e"></a><table>
<caption><span>Table 5. Subcutaneous NovoLog Administration in Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (6 months; n=176)</span></caption>
<col width="57%">
<col width="21%">
<col width="22%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Values are Mean ± SD</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> refers to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> associated with central nervous system symptoms and requiring the intervention of another person or hospitalization.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">NovoLog + NPH</p></td>
<td class="Botrule Toprule" align="center"><p class="First">Novolin R + NPH</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">N</p></td>
<td class="Botrule Rrule" align="center"><p class="First">90</p></td>
<td class="Botrule" align="center"><p class="First">86</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline HbA (%)
                                                    <span class="Sub">1c</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.1 ± 1.2</p></td>
<td class="Botrule" align="center"><p class="First">7.8 ± 1.1</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Change from Baseline HbA (%)
                                                    <span class="Sub">1c</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">-0.3 ± 1.0</p></td>
<td class="Botrule" align="center"><p class="First">-0.1 ± 0.8</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Treatment Difference in HbA Mean (95% confidence interval)
                                                    <span class="Sub">1c,</span></p></td>
<td class="Botrule" align="center" colspan="2"><p class="First">- 0.1 (-0.4, -0.1)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline insulin dose (IU/kg/24 hours)
                                                    <a href="#footnote-7" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.6 ± 0.3</p></td>
<td class="Botrule" align="center"><p class="First">0.6 ± 0.3</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">End-of-Study insulin dose (IU/kg/24 hours)
                                                    <a href="#footnote-7" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 ± 0.3</p></td>
<td class="Botrule" align="center"><p class="First">0.7 ± 0.3</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Patients with severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (n, %)
                                                    <a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">9 (10%)</p></td>
<td class="Botrule" align="center"><p class="First">5 (8%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule">
<p class="First">Baseline body weight (kg)
                                                    <a href="#footnote-7" class="Sup">*</a></p>
<p>Weight Change from baseline (kg)
                                                    <a href="#footnote-7" class="Sup">*</a></p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">88.4 ± 13.3</p>
<p>1.2 ± 3.0</p>
</td>
<td class="Botrule" align="center">
<p class="First">85.8 ± 14.8</p>
<p>0.4 ± 3.1</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fd25200a-a408-41a2-9ad7-e489f1ef239e"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Continuous Subcutaneous Insulin Infusion (CSII) by External Pump</h2>
<p class="First">Two open-label, parallel design studies (6 weeks [n=29] and 16 weeks [n=118]) compared NovoLog to buffered regular human insulin (Velosulin) in adults with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> receiving a subcutaneous infusion with an external insulin pump. The two treatment regimens had comparable changes in HbA and rates of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.
                                    <span class="Sub">1c</span></p>
<a name="_Refid_34bd364f-c7ed-456e-9565-bd73f878b"></a><table>
<caption><span>Table 6. Adult Insulin Pump Study in Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (16 weeks; n=118)</span></caption>
<col width="55%">
<col width="18%">
<col width="27%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Values are Mean ± SD</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> refers to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> associated with central nervous system symptoms and requiring the intervention of another person or hospitalization.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">NovoLog</p></td>
<td class="Botrule Toprule" align="center"><p class="First">Buffered human insulin</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">N</p></td>
<td class="Botrule Rrule" align="center"><p class="First">59</p></td>
<td class="Botrule" align="center"><p class="First">59</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline HbA (%)
                                                    <span class="Sub">1c</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">7.3 ± 0.7</p></td>
<td class="Botrule" align="center"><p class="First">7.5 ± 0.8</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Change from Baseline HbA (%)
                                                    <span class="Sub">1c</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.0 ± 0.5</p></td>
<td class="Botrule" align="center"><p class="First">0.2 ± 0.6</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Treatment Difference in HbA Mean (95% confidence interval)
                                                    <span class="Sub">1c,</span></p></td>
<td class="Botrule" align="center" colspan="2"><p class="First">0.3 (-0.1, 0.4)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline insulin dose (IU/kg/24 hours)
                                                    <a href="#footnote-9" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 ± 0.8</p></td>
<td class="Botrule" align="center"><p class="First">0.6 ± 0.2</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">End-of-Study insulin dose (IU/kg/24 hours)
                                                    <a href="#footnote-9" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 ± 0.7</p></td>
<td class="Botrule" align="center"><p class="First">0.6 ± 0.2</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Patients with severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (n, %)
                                                    <a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2%)</p></td>
<td class="Botrule" align="center"><p class="First">2 (3%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule">
<p class="First">Baseline body weight (kg)
                                                    <a href="#footnote-9" class="Sup">*</a></p>
<p>Weight Change from baseline (kg)
                                                    <a href="#footnote-9" class="Sup">*</a></p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">77.4 ± 16.1</p>
<p>0.1 ± 3.5</p>
</td>
<td class="Botrule" align="center">
<p class="First">74.8 ± 13.8</p>
<p>-0.0 ± 1.7</p>
</td>
</tr>
</tbody>
</table>
<p>A randomized, 16-week, open-label, parallel design study of children and adolescents with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (n=298) aged 4-18 years compared two subcutaneous infusion regimens administered via an external insulin pump: NovoLog (n=198) or insulin lispro (n=100). These two treatments resulted in comparable changes from baseline in HbA and comparable rates of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> after 16 weeks of treatment (see ).
                                    <span class="Sub">1c</span><a href="#_Refid_59416680-8021-49ab-a464-50611b24e">Table 7</a></p>
<a name="_Refid_59416680-8021-49ab-a464-50611b24e"></a><table>
<caption><span>Table 7. Pediatric Insulin Pump Study in Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (16 weeks; n=298)</span></caption>
<col width="61%">
<col width="19%">
<col width="20%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Values are Mean ± SD</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> refers to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> associated with central nervous system symptoms and requiring the intervention of another person or hospitalization.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">NovoLog</p></td>
<td class="Botrule Toprule" align="center"><p class="First">Lispro</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">N</p></td>
<td class="Botrule Rrule" align="center"><p class="First">198</p></td>
<td class="Botrule" align="center"><p class="First">100</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline HbA (%)
                                                    <span class="Sub">1c</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.0 ± 0.9</p></td>
<td class="Botrule" align="center"><p class="First">8.2 ± 0.8</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Change from Baseline HbA (%)
                                                    <span class="Sub">1c</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">-0.1 ± 0.8</p></td>
<td class="Botrule" align="center"><p class="First">-0.1 ± 0.7</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Treatment Difference in HbA Mean (95% confidence interval)
                                                    <span class="Sub">1c,</span></p></td>
<td class="Botrule" align="center" colspan="2"><p class="First">-0.1 (-0.3, 0.1)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline insulin dose (IU/kg/24 hours)
                                                    <a href="#footnote-11" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.9 ± 0.3</p></td>
<td class="Botrule" align="center"><p class="First">0.9 ± 0.3</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">End-of-Study insulin dose (IU/kg/24 hours)
                                                    <a href="#footnote-11" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.9 ± 0.2</p></td>
<td class="Botrule" align="center"><p class="First">0.9 ± 0.2</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Patients with severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (n, %)
                                                    <a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">19 (10%)</p></td>
<td class="Botrule" align="center"><p class="First">8 (8%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic ketoacidosis</span> (n, %)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (0.5%)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule">
<p class="First">Baseline body weight (kg)
                                                    <a href="#footnote-11" class="Sup">*</a></p>
<p>Weight Change from baseline (kg)
                                                    <a href="#footnote-11" class="Sup">*</a></p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">54.1 ± 19.7</p>
<p>1.8 ± 2.1</p>
</td>
<td class="Botrule" align="center">
<p class="First">55.5 ± 19.0</p>
<p>1.6 ± 2.1</p>
</td>
</tr>
</tbody>
</table>
<p>An open-label, 16-week parallel design trial compared pre-prandial NovoLog injection in conjunction with NPH injections to NovoLog administered by continuous subcutaneous infusion in 127 adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The two treatment groups had similar reductions in HbA and rates of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> ( ) [ ].
                                    <span class="Sub">1c</span><a href="#_Refid_919ee2ab-69c3-4dbf-b7cb-eb9ffd779">Table 8</a><span class="Italics">see , , and
                                        <a href="#i4i_indications_id_83845130-81bc-4e0f-bd80-489124b5a5ad">Indications and Usage (1)</a><a href="#i4i_dosage_admin_id_73e1ff2e-eaa5-46c5-98cb-77f43e3785c2">Dosage and Administration (2)</a><a href="#i4i_warnings_precautions_id_4bc7c883-0765-44cd-8028-c744ee1c4853">Warnings and Precautions (5)</a><a href="#i4i_storage_id_af41a3f6-59d7-4db1-a09e-3b81ed0d89f3">How Supplied/Storage and Handling (16.2)</a></span></p>
<a name="_Refid_919ee2ab-69c3-4dbf-b7cb-eb9ffd779"></a><table>
<caption><span>Table 8. Pump Therapy in Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (16 weeks; n=127)</span></caption>
<col width="61%">
<col width="19%">
<col width="20%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>Values are Mean ± SD</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">NovoLog pump</p></td>
<td class="Botrule Toprule" align="center"><p class="First">NovoLog + NPH</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">N</p></td>
<td class="Botrule Rrule" align="center"><p class="First">66</p></td>
<td class="Botrule" align="center"><p class="First">61</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline HbA (%)
                                                    <span class="Sub">1c</span><a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.2 ± 1.4</p></td>
<td class="Botrule" align="center"><p class="First">8.0 ± 1.1</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Change from Baseline HbA (%)
                                                    <span class="Sub">1c</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">-0.6 ± 1.1</p></td>
<td class="Botrule" align="center"><p class="First">-0.5 ± 0.9</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Treatment Difference in HbA Mean (95% confidence interval)
                                                    <span class="Sub">1c,</span></p></td>
<td class="Botrule" align="center" colspan="2"><p class="First">0.1 (0.4, 0.3)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline insulin dose (IU/kg/24 hours)
                                                    <a href="#footnote-13" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.7 ± 0.3</p></td>
<td class="Botrule" align="center"><p class="First">0.8 ± 0.5</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">End-of-Study insulin dose (IU/kg/24 hours)
                                                    <a href="#footnote-13" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.9 ± 0.4</p></td>
<td class="Botrule" align="center"><p class="First">0.9 ± 0.5</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule">
<p class="First">Baseline body weight (kg)
                                                    <a href="#footnote-13" class="Sup">*</a></p>
<p>Weight Change from baseline (kg)
                                                    <a href="#footnote-13" class="Sup">*</a></p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">96.4 ± 17.0</p>
<p>1.7 ± 3.7</p>
</td>
<td class="Botrule" align="center">
<p class="First">96.9 ± 17.9</p>
<p>0.7 ± 4.1</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_827b7840-f275-497e-949f-c815bfb19151"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Intravenous Administration of NovoLog</h2>
<p class="First">See .
                                    <span class="Italics">Section
                                        <a href="#i4i_pharmacodynamics_id_c2ce926d-4148-4445-a300-fa67506910f8">12.2 CLINICAL PHARMACOLOGY/Pharmacodynamics</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_fd0dcf7e-b877-436d-9d3f-f9023f53f1f0"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC:64725-0750-1 in a VIAL, GLASS of 10 INJECTION, SOLUTIONS</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_920fec1f-d6e3-49b0-9f11-b13ac921e736"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">NovoLog is available in the following package sizes: each presentation containing 100 Units of insulin aspart per mL (U-100).</p>
<table>
<col width="61%">
<col width="40%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>NovoLog PenFill cartridges are designed for use with Novo Nordisk 3 mL PenFill cartridge compatible insulin delivery devices (with or without the addition of a NovoPen 3 PenMate) with NovoFine disposable needles. FlexPen and FlexTouch can be used with NovoFine or NovoTwist disposable needles.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"><p class="First">10 mL vials</p></td>
<td class="Botrule Toprule" align="center"><p class="First">NDC 0169-7501-11</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">3 mL PenFill  cartridges
                                                    <a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a></p></td>
<td class="Botrule" align="center"><p class="First">NDC 0169-3303-12</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">3 mL NovoLog FlexPen</p></td>
<td class="Botrule" align="center"><p class="First">NDC 0169-6339-10</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">3 mL NovoLog FlexTouch</p></td>
<td class="Botrule" align="center"><p class="First">NDC 0169-6338-10</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_af41a3f6-59d7-4db1-a09e-3b81ed0d89f3"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Recommended Storage</h2>
<p class="First">Unused NovoLog should be stored in a refrigerator between 2° and 8°C (36° to 46°F). Do not store in the freezer or directly adjacent to the refrigerator cooling element.  NovoLog should not be drawn into a syringe and stored for later use.
                                    <span class="Bold">Do not freeze NovoLog and do not use NovoLog if it has been frozen.</span></p>
<p>After initial use a vial may be kept at temperatures below 30°C (86°F) for up to 28 days, but should not be exposed to excessive heat or light. Opened vials may be refrigerated.
                                    <span class="Bold"><span class="Italics">Vials:</span></span></p>
<p>Unpunctured vials can be used until the expiration date printed on the label if they are stored in a refrigerator. Keep unused vials in the carton so they will stay clean and protected from light.</p>
<p><span class="Bold"><span class="Italics">PenFill cartridges or NovoLog FlexPen and NovoLog FlexTouch:</span></span></p>
<p>Once a cartridge or NovoLog FlexPen or NovoLog FlexTouch is punctured, it should be kept at temperatures below 30°C (86°F) for up to 28 days, but should not be exposed to excessive heat or sunlight. A NovoLog FlexPen or NovoLog FlexTouch or cartridge in use must NOT be stored in the refrigerator.  Keep the NovoLog FlexPen or NovoLog FlexTouch and all PenFill cartridges away from direct heat and sunlight. Unpunctured NovoLog FlexPen or NovoLog FlexTouch and PenFill cartridges can be used until the expiration date printed on the label if they are stored in a refrigerator. Keep unused NovoLog FlexPen or NovoLog FlexTouch and PenFill cartridges in the carton so they will stay clean and protected from light.</p>
<p><span class="Bold">Always remove the needle after each injection and store the 3 mL PenFill cartridge delivery device or NovoLog FlexPen or NovoLog FlexTouch without a needle attached. This prevents contamination and/or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or leakage of insulin, and will ensure accurate dosing. Always use a new needle for each injection to prevent contamination.</span></p>
<p><span class="Bold"><span class="Italics">Pump:</span></span></p>
<p>NovoLog in the pump reservoir should be discarded after at least every 6 days of use or after exposure to temperatures that exceed 37°C (98.6°F). The infusion set and the infusion set insertion site should be changed at least every 3 days.</p>
<p><span class="Bold"><span class="Italics">Summary of Storage Conditions:</span></span></p>
<p>The storage conditions are summarized in the following table:</p>
<a name="_Refid_6a1cb763-f232-4348-a615-cbc6ab4c8"></a><table>
<caption><span>Table 9. Storage conditions for vial, PenFill cartridges, NovoLog FlexPen, and NovoLog FlexTouch</span></caption>
<col width="28%">
<col width="25%">
<col width="22%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule">
<p class="First">NovoLog</p>
<p>presentation</p>
</td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">Room Temperature (below 30°C)
                                                    <span class="Bold">Not in-use (unopened)</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">Refrigerated
                                                    <span class="Bold">Not in-use (unopened)</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First">Room Temperature (below 30°C)
                                                    <span class="Bold">In-use (opened)</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">10 mL vial</p></td>
<td class="Botrule Rrule" align="center"><p class="First">28 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Until expiration date</p></td>
<td class="Botrule" align="center"><p class="First">28 days (refrigerated/room temperature)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">3 mL PenFill cartridges</p></td>
<td class="Botrule Rrule" align="center"><p class="First">28 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Until expiration date</p></td>
<td class="Botrule" align="center">
<p class="First">28 days</p>
<p>(Do not refrigerate)</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">3 mL NovoLog FlexPen</p></td>
<td class="Botrule Rrule" align="center"><p class="First">28 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Until expiration date</p></td>
<td class="Botrule" align="center">
<p class="First">28 days</p>
<p>(Do not refrigerate)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">3 mL NovoLog FlexTouch</p></td>
<td class="Botrule Rrule" align="center"><p class="First">28 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Until expiration date</p></td>
<td class="Botrule" align="center">
<p class="First">28 days</p>
<p>(Do not refrigerate)</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Storage of Diluted NovoLog</span></span></p>
<p>NovoLog diluted with Insulin Diluting Medium for NovoLog to a concentration equivalent to U-10 or equivalent to U-50 may remain in patient use at temperatures below 30°C (86°F) for 28 days.</p>
<p><span class="Bold"><span class="Italics">Storage of NovoLog in Infusion Fluids</span></span></p>
<p>Infusion bags prepared as indicated under are stable at room temperature for 24 hours. Some insulin will be initially adsorbed to the material of the infusion bag.
                                    <span class="Italics">Dosage and Administration (2)</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_74a7af07-8011-4ddf-9fbc-46a57c903e96"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">[See ]
                            <span class="Italics"><a href="#i4i_section_id_ff72b441-a22d-4016-912c-873bdc8761a1">FDA Approved Patient Labeling (17.3)</a></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a224ae15-9793-4429-95ca-d58da49ff3b5"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Physician Instructions</h2>
<p class="First">Maintenance of normal or near-normal glucose control is a treatment goal in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and has been associated with a reduction in diabetic complications. Patients should be informed about potential risks and benefits of NovoLog therapy including the possible adverse reactions. Patients should also be offered continued education and advice on insulin therapies, injection technique, life-style management, regular glucose monitoring, periodic <span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">glycosylated hemoglobin</span> testing, recognition and management of hypo- and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, adherence to meal planning, complications of insulin therapy, timing of dose, instruction in the use of injection or subcutaneous infusion devices, and proper storage of insulin. Patients should be informed that frequent, patient-performed blood glucose measurements are needed to achieve optimal glycemic control and avoid both hyper- and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p>Patients should receive proper training on how to use NovoLog. Instruct patients that when injecting NovoLog, they must press and hold down the dose button until the dose counter shows 0 and then keep the needle in the skin and count slowly to 6. When the dose counter returns to 0, the prescribed dose is not completely delivered until 6 seconds later. If the needle is removed earlier, they may see a stream of insulin coming from the needle tip.  If so, the full dose will not be delivered (a possible under-dose may occur by as much as 20%), and they should increase the frequency of checking their blood glucose levels and possible additional insulin administration may be necessary.</p>
<dl>
<dt>•</dt>
<dd>If 0 does not appear in the dose counter after continuously pressing the dose button, the patient may have used a blocked needle. In this case they would have received insulin – even though the dose counter has moved from the original dose that was set.
                                        <span class="Bold">not</span><span class="Bold">any</span>
</dd>
<dt>•</dt>
<dd>If the patient did have a blocked needle, instruct them to change the needle as described in Section 5 of the Instructions for Use and repeat all steps in the IFU starting with Section 1: Prepare your pen with a new needle.
                                        <span class="Bold">Make sure the patient selects the full dose needed.</span>
</dd>
</dl>
<p>The patient’s ability to concentrate and react may be impaired as a result of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. Patients who have frequent <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or reduced or absent warning signs of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> should be advised to use caution when driving or operating machinery.</p>
<p>Accidental substitutions between NovoLog and other insulin products have been reported. Patients should be instructed to always carefully check that they are administering the appropriate insulin to avoid medication errors between NovoLog and any other insulin.
                                    <span class="Bold">The written prescription for NovoLog should be written clearly, to avoid <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> with other insulin products, for example, NovoLog Mix 70/30.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_14ea1a11-7dc4-4eec-bc4c-532bc90c5d4d"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Patients Using Pumps</h2>
<p class="First">Patients using external pump infusion therapy should be trained in intensive insulin therapy with multiple injections and in the function of their pump and pump accessories.</p>
<p>The following insulin pumps† have been used in NovoLog clinical or studies conducted by Novo Nordisk, the manufacturer of NovoLog:
                                    <span class="Italics">in vitro</span></p>
<dl>
<dt>•</dt>
<dd>Medtronic Paradigm 512 and 712
                                        <span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>MiniMed 508
                                        </dd>
<dt>•</dt>
<dd>Disetronic D-TRON and H-TRON
                                        <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span>
</dd>
</dl>
<p>Before using another insulin pump with NovoLog, read the pump label to make sure the pump has been evaluated with NovoLog.</p>
<p>NovoLog is recommended for use in any reservoir and infusion sets that are compatible with insulin and the specific pump. Please see recommended reservoir and infusion sets in the pump manual.</p>
<p><span class="Bold">To avoid insulin degradation, infusion set occlusion, and loss of the preservative (metacresol), insulin in the reservoir should be replaced at least every 6 days; infusion sets and infusion set insertion sites should be changed at least every 3 days.</span></p>
<p>° ° The temperature of the insulin may exceed ambient temperature when the pump housing, cover, tubing, or sport case is exposed to sunlight or radiant heat. Infusion sites that are erythematous, pruritic, or thickened should be reported to medical personnel, and a new site selected because continued infusion may increase the <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> and/or alter the absorption of NovoLog. Pump or infusion set malfunctions or insulin degradation can lead to <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="4101761" conceptname="Ketosis">ketosis</span> in a short time because of the small subcutaneous depot of insulin. This is especially pertinent for rapid-acting insulin analogs that are more rapidly absorbed through skin and have shorter duration of action. These differences are particularly relevant when patients are switched from multiple injection therapy. Prompt identification and correction of the cause of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> or <span class="product-label-link" type="condition" conceptid="4101761" conceptname="Ketosis">ketosis</span> is necessary. Problems include pump malfunction, infusion set occlusion, leakage, disconnection or kinking, and degraded insulin. Less commonly, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> from pump malfunction may occur. If these problems cannot be promptly corrected, patients should resume therapy with subcutaneous insulin injection and contact their physician [ ].
                                    <span class="Bold">Insulin exposed to temperatures higher than 37</span><span class="Bold">C (98.6</span><span class="Bold">F) should be discarded.</span><span class="Italics">see , and
                                        <a href="#i4i_dosage_admin_id_73e1ff2e-eaa5-46c5-98cb-77f43e3785c2">Dosage and Administration (2)</a><a href="#i4i_warnings_precautions_id_4bc7c883-0765-44cd-8028-c744ee1c4853">Warnings and Precautions (5)</a><a href="#i4i_storage_id_af41a3f6-59d7-4db1-a09e-3b81ed0d89f3">How Supplied/Storage and Handling (16.2)</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ff72b441-a22d-4016-912c-873bdc8761a1"></a><a name="section-15.3"></a><p></p>
<h2>17.3 FDA Approved Patient Labeling </h2>
<p class="First"><a href="#i4i_patient_package_insert_id_6ec0955f-b08b-4fab-9bf1-c3815b9f66bb">See separate leaflet.</a></p>
<p><span class="Bold">Rx only</span></p>
<p>Date of Issue: April 25, 2014</p>
<p>Version: 22</p>
<p><span class="Italics">Novo Nordisk , NovoLog , NovoPen 3, PenFill , Novolin , FlexPen , FlexTouch , PenMate , NovoFine and NovoTwist are registered trademarks of Novo Nordisk A/S.
                                        <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span></span></p>
<p><span class="Italics">NovoLog is covered by US Patent Nos. 5,618,913, 5,866,538, and other patents pending.
                                        <span class="Sup">®</span></span></p>
<p><span class="Italics">FlexPen is covered by US Patent Nos. RE 41,956, 6,004,297, RE 43,834, and other patents pending.
                                        <span class="Sup">®</span></span></p>
<p><span class="Italics">FlexTouch pen is covered by US Patent Nos. 7,686,786, 6,899,699, and other patents pending.
                                        <span class="Sup">®</span></span></p>
<p><span class="Italics">PenFill is covered by US Patent No. 5,693,027.
                                        <span class="Sup">®</span></span></p>
<p><span class="Italics">†The brands listed are the registered trademarks of their respective owners and are not trademarks of Novo Nordisk A/S.</span></p>
<p>© 2002-2014 Novo Nordisk</p>
<p>Manufactured by:</p>
<p>Novo Nordisk A/S</p>
<p>DK-2880 Bagsvaerd, Denmark</p>
<p>For information about NovoLog contact:</p>
<p>Novo Nordisk Inc.</p>
<p>800 Scudders Mill Road</p>
<p>Plainsboro, New Jersey 08536</p>
<p>1-800-727-6500</p>
<p>www.novonordisk-us.com</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_6ec0955f-b08b-4fab-9bf1-c3815b9f66bb"></a><a name="section-16"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">NovoLog (NŌ-v?-log)
                                <span class="Sup">®</span></span></p>
<p>(insulin aspart [rDNA origin] injection)</p>
<p><span class="Bold">What is NovoLog?</span></p>
<dl>
<dt>•</dt>
<dd>NovoLog is a man-made insulin that is used to control high blood sugar in adults and children with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.
                                </dd>
</dl>
<p><span class="Bold">Who should not take NovoLog?</span></p>
<p><span class="Bold">Do not take NovoLog if you:</span></p>
<dl>
<dt>•</dt>
<dd>are having an episode of low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>).
                                </dd>
<dt>•</dt>
<dd>have an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to NovoLog or any of the ingredients in NovoLog.
                                </dd>
</dl>
<p><span class="Bold">Before taking NovoLog, tell your healthcare provider about all your medical conditions including, if you are:</span></p>
<dl>
<dt>•</dt>
<dd>pregnant, planning to become pregnant, or are breastfeeding.
                                </dd>
<dt>•</dt>
<dd>taking new prescription or over-the-counter medicines, vitamins, or herbal supplements.
                                </dd>
</dl>
<p><span class="Bold">Before you start taking NovoLog, talk to your healthcare provider about low blood sugar and how to manage it.</span></p>
<p><span class="Bold">How should I take NovoLog?</span></p>
<dl>
<dt>•</dt>
<dd>that come with your NovoLog.
                                <span class="Bold">Read theInstructions for Use</span>
</dd>
<dt>•</dt>
<dd>Take NovoLog exactly as your healthcare provider tells you to.
                                </dd>
<dt>•</dt>
<dd>You should eat a meal within 5 to 10 minutes after you take your dose of NovoLog.
                                <span class="Bold">NovoLog starts acting fast.</span>
</dd>
<dt>•</dt>
<dd>Know the type and strength of insulin you take. change the type of insulin you take unless your healthcare provider tells you to. The amount of insulin and the best time for you to take your insulin may need to change if you take different types of insulin.
                                <span class="Bold">Do not</span>
</dd>
<dt>•</dt>
<dd>Ask your healthcare provider what your blood sugars should be and when you should check your blood sugar levels.
                                <span class="Bold">Check your blood sugar levels.</span>
</dd>
<dt>•</dt>
<dd>You may give another person an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or get an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> from them.
                                <span class="Bold">Do not share your NovoLog FlexPen, FlexTouch or needles with another person.</span>
</dd>
</dl>
<p><span class="Bold">What should I avoid while taking NovoLog?</span></p>
<p><span class="Bold">While taking NovoLog do not:</span></p>
<dl>
<dt>•</dt>
<dd>Drive or operate heavy machinery, until you know how NovoLog affects you.
                                </dd>
<dt>•</dt>
<dd>Drink alcohol or use prescription or over-the-counter medicines that contain alcohol.
                                </dd>
</dl>
<p><span class="Bold">What are the possible side effects of NovoLog?</span></p>
<p><span class="Bold">NovoLog may cause serious side effects that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, including:</span></p>
<p>Signs and symptoms that may indicate low blood sugar include:
                            <span class="Bold">Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>).</span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or light-headedness
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, or <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>
                                </dd>
<dt>•</dt>
<dd>fast heart beat
                                </dd>
</dl>
<p><span class="Bold">Your insulin dose may need to change because of:</span></p>
<dl>
<dt>•</dt>
<dd>change in level of physical activity or exercise
                                </dd>
<dt>•</dt>
<dd>increased stress
                                </dd>
<dt>•</dt>
<dd>change in diet
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or loss
                                </dd>
<dt>•</dt>
<dd>illness
                                </dd>
</dl>
<p><span class="Bold">Other common side effects of NovoLog may include:</span></p>
<dl>
<dt>•</dt>
<dd>low potassium in your blood (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>), reactions at the injection site, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (whole body reactions), skin thickening or pits at the injection site (<span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>), <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your hands and feet.
                                </dd>
</dl>
<p><span class="Bold">Get emergency medical help if you have:</span></p>
<dl>
<dt>•</dt>
<dd>trouble breathing, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, fast heartbeat, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, tongue, or throat, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.
                                </dd>
</dl>
<p>These are not all the possible side effects of NovoLog. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">General information about the safe and effective use of NovoLog.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about NovoLog that is written for health professionals. Do not use NovoLog for a condition for which it was not prescribed. Do not give NovoLog to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p><span class="Bold">What are the ingredients in NovoLog?</span></p>
<p>insulin aspart  (rDNA origin)
                            <span class="Bold">Active Ingredient:</span></p>
<p>glycerin, phenol, metacresol, zinc, disodium hydrogen phosphate dihydrate, sodium chloride and water for injection
                            <span class="Bold">Inactive Ingredients:</span></p>
<p><span class="Bold">Manufactured by:</span></p>
<p>Novo Nordisk A/S</p>
<p>DK-2880 Bagsvaerd, Denmark</p>
<p>For more information, go to www.novonordisk-us.com or call 1-800-727-6500.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration</p>
<p>Revised: 10/2013</p>
<div class="Figure">
<a name="id516807598"></a><img alt="QR Code" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-05.jpg">
</div>
<p>For more information go to</p>
<p><a href="http://www.novologflextouch.com">www.novologflextouch.com</a></p>
<p>© 2002-2013 Novo Nordisk</p>
<div class="Figure">
<a name="id1972935968"></a><img alt="Cover Page" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-06.jpg">
</div>
<p><span class="Bold">PATIENT INSTRUCTIONS FOR USE</span></p>
<p><span class="Bold">NovoLog (NŌ-v?-log)
                                <span class="Sup">®</span></span></p>
<p><span class="Bold">(insulin aspart [rDNA origin] injection)</span></p>
<p><span class="Bold">10 mL vial (100 Units/mL, U-100)</span></p>
<p>Read this Instructions for Use before you start taking NovoLog and each time you get a refill.  There may be new information.  This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
                            <span class="Bold"><span class="Sup">®</span></span></p>
<p><span class="Bold">Supplies you will need to give your NovoLog injection:
                                <span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd>10 mL NovoLog vial
                                <span class="Bold"><span class="Sup">®</span></span>
</dd>
<dt>•</dt>
<dd>insulin syringe and needle
                                </dd>
<dt>•</dt>
<dd>alcohol swab
                                </dd>
</dl>
<div class="Figure">
<a name="id354392903"></a><img alt="Vial figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-07.jpg">
</div>
<p><span class="Bold">Preparing your NovoLog dose:
                                <span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd>Wash your hands with soap and water.
                                </dd>
<dt>•</dt>
<dd>Before you start to prepare your injection, check the NovoLog label to make sure that you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin.
                                <span class="Bold"><span class="Sup">®</span></span>
</dd>
<dt>•</dt>
<dd>NovoLog should look clear and colorless. use NovoLog if it is thick, cloudy, or is colored.
                                <span class="Bold"><span class="Sup">®</span></span><span class="Bold">Do not</span><span class="Bold"><span class="Sup">®</span></span>
</dd>
<dt>•</dt>
<dd>use NovoLog past the expiration date printed on the label.
                                <span class="Bold">Do not</span><span class="Bold"><span class="Sup">®</span></span>
</dd>
</dl>
<div class="Figure">
<a name="id-137579482"></a><img alt="Hand and vial figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-08.jpg">
</div>
<p>Pull off the tamper resistant cap (See Figure A).
                            <span class="Bold">Step 1:</span></p>
<p>Wipe the rubber stopper with an alcohol swab (See Figure B).
                            <span class="Bold">Step 2:</span></p>
<div class="Figure">
<a name="id-1250654504"></a><img alt="Figure A and Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-09.jpg">
</div>
<p>Hold the syringe with the needle pointing up.Pull down on the plunger until the black tip reaches the line for the number of units for your prescribed dose (See Figure C).
                            <span class="Bold">Step 3:</span></p>
<div class="Figure">
<a name="id123892494"></a><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-10.jpg">
</div>
<p>Push the needle through the rubber stopper of the NovoLog vial (See Figure D).
                            <span class="Bold">Step 4:</span><span class="Bold"><span class="Sup">®</span></span></p>
<div class="Figure">
<a name="id447511149"></a><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-11.jpg">
</div>
<p>Push the plunger all the way in. This puts air into the NovoLog vial (See Figure E).
                            <span class="Bold">Step 5:</span><span class="Bold"><span class="Sup">®</span></span></p>
<div class="Figure">
<a name="id426391719"></a><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-12.jpg">
</div>
<p>Turn the NovoLog vial and syringe upside down and slowly pull the plunger down until the black tip is a few units past the line for your dose (See Figure F).
                            <span class="Bold">Step 6:</span><span class="Bold"><span class="Sup">®</span></span></p>
<div class="Figure">
<a name="id-1499883398"></a><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-13.jpg">
</div>
<dl>
<dt>•</dt>
<dd>If there are air bubbles, tap the syringe gently a few times to let any air bubbles rise to the top (See Figure G).
                                </dd>
</dl>
<div class="Figure">
<a name="id151418724"></a><img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-14.jpg">
</div>
<p>Slowly push the plunger up until the black tip reaches the line for your NovoLog dose (See Figure H).
                            <span class="Bold">Step 7:</span><span class="Bold"><span class="Sup">®</span></span></p>
<div class="Figure">
<a name="id-400838923"></a><img alt="Figure H" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-15.jpg">
</div>
<p>Check the syringe to make sure you have the right dose of NovoLog .
                            <span class="Bold">Step 8:</span><span class="Sup">®</span></p>
<p>Pull the syringe out of the vial’s rubber stopper (See Figure I).
                            <span class="Bold">Step 9:</span></p>
<div class="Figure">
<a name="id-1225979460"></a><img alt="Figure I" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-16.jpg">
</div>
<dl>
<dt> </dt>
<dd><span class="Bold">Giving your Injection:</span></dd>
</dl>
<dl>
<dt>•</dt>
<dd>Inject your NovoLog exactly as your healthcare provider has shown you.  Your healthcare provider should tell you if you need to pinch the skin before injecting.
                                <span class="Bold"><span class="Sup">®</span></span>
</dd>
<dt>•</dt>
<dd>NovoLog can be injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms, infused in an insulin pump, or given through a needle in your arm (intravenously) by your healthcare provider.
                                <span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>If you inject NovoLog ,change (rotate) your injection sites within the area you choose for each dose. use the same injection site for each injection.
                                <span class="Sup">®</span><span class="Bold">Do not</span>
</dd>
<dt>•</dt>
<dd>If you use NovoLog in an insulin pump, you should change your insertion site every 3 days. The insulin in the reservoir should be changed at least every 6 days even if you have not used all of the insulin.
                                <span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>If you use NovoLog in an insulin pump, see your insulin pump manual for instructions or talk to your healthcare provider.
                                <span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>NPH insulin is the only type of insulin that can be mixed with NovoLog . mix NovoLog with any other type of insulin.
                                <span class="Sup">®</span><span class="Bold">Do not</span><span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>NovoLog should be mixed with NPH insulin if it is going to be injected right away under your skin (subcutaneously).
                                <span class="Sup">®</span><span class="Bold">only</span>
</dd>
<dt>•</dt>
<dd>NovoLog should be drawn up into the syringe you draw up your NPH insulin.
                                <span class="Sup">®</span><span class="Bold">before</span>
</dd>
<dt>•</dt>
<dd>Talk to your healthcare provider if you are not sure about the right way to mix NovoLog and NPH insulin.
                                <span class="Sup">®</span>
</dd>
</dl>
<p>Choose your injection site and wipe the skin with an alcohol swab.  Let the injection site dry before you inject your dose (See Figure J).
                            <span class="Bold">Step 10:</span></p>
<div class="Figure">
<a name="id-1553915433"></a><img alt="Figure J" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-17.jpg">
</div>
<p>Insert the needle into your skin.  Push down on the plunger to inject your dose (See Figure K).
                            <span class="Bold">Step 11:</span><span class="Bold">Needle should remain in the skin for at least 6 seconds to make sure you have injected all the insulin.</span></p>
<div class="Figure">
<a name="id-729842138"></a><img alt="Figure K" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-18.jpg">
</div>
<p>Pull the needle out of your skin.  After that, you may see a drop of NovoLog at the needle tip. This is normal and does not affect the dose you just received (See Figure L).
                            <span class="Bold">Step 12:</span><span class="Sup">®</span></p>
<dl>
<dt>•</dt>
<dd>If you see blood after you take the needle out of your skin, press the injection site lightly with a
                                </dd>
<dt> </dt>
<dd>piece of gauze or an alcohol swab. rub the area.
                                <span class="Bold">Do not</span>
</dd>
</dl>
<div class="Figure">
<a name="id-899287785"></a><img alt="Figure L" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-19.jpg">
</div>
<p><span class="Bold">After your injection:</span></p>
<dl>
<dt>•</dt>
<dd>recap the needle.  Recapping the needle can lead to a needle stick injury.
                                <span class="Bold">Do not</span>
</dd>
<dt>•</dt>
<dd>Throw away empty insulin vials, used syringes, and needles in a sharps container or some type of hard plastic or metal container with a screw on cap such as a detergent bottle or empty coffee can.  Check with your healthcare provider about the right way to throw away the container.  There may be local or state laws about how to throw away used syringes and needles.  Do not throw away used syringes and needles in household trash or recycling bins.
                                </dd>
</dl>
<p><span class="Bold">How should I store NovoLog ?
                                <span class="Sup">®</span></span></p>
<p>freeze NovoLog . use NovoLog if it has been frozen.
                            <span class="Bold">Do not</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold">Do not</span><span class="Bold"><span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd>Keep NovoLog away from heat or light.
                                <span class="Bold"><span class="Sup">®</span></span>
</dd>
<dt>•</dt>
<dd>Store opened and unopened NovoLog vials in the refrigerator at 36 F to 46 F (2 C to 8 C).  Opened NovoLog vials can also be stored out of the refrigerator below 86 F (30 C).
                                <span class="Bold"><span class="Sup">®</span></span><span class="Sup">O</span><span class="Sup">O</span><span class="Sup">O</span><span class="Sup">O</span><span class="Bold"><span class="Sup">®</span></span><span class="Sup">O</span><span class="Sup">O</span>
</dd>
<dt>•</dt>
<dd>Unopened vials may be used until the expiration date printed on the label, if they are kept in the refrigerator.
                                </dd>
<dt>•</dt>
<dd>Opened NovoLog vials should be thrown away after 28 days, even if they still have insulin left in them.
                                <span class="Bold"><span class="Sup">®</span></span>
</dd>
</dl>
<p><span class="Bold">General information about the safe and effective use of NovoLog
                                <span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd>Always use a new syringe and needle for each injection.
                                </dd>
<dt>•</dt>
<dd>Do not share syringes or needles.
                                </dd>
<dt>•</dt>
<dd>Keep NovoLog vials, syringes, and needles out of the reach of children.
                                <span class="Bold"><span class="Sup">®</span></span>
</dd>
</dl>
<p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured by:</p>
<p>Novo Nordisk A/S</p>
<p>DK-2880 Bagsvaerd, Denmark</p>
<p>.
                            <span class="Italics">NovoLog is a registered trademark of Novo Nordisk A/S
                                <span class="Sup">®</span></span></p>
<p>NovoLog is covered by US Patent Nos. 5,618,913, 5,866,538, and other patents pending.
                            <span class="Sup">®</span></p>
<p>© 2002-2013 Novo Nordisk</p>
<p>For information about NovoLog contact:
                            <span class="Sup">®</span></p>
<p>Novo Nordisk Inc.</p>
<p>800 Scudders Mill Road</p>
<p>Plainsboro, New Jersey 08536</p>
<p>1-800-727-6500</p>
<p>www.novonordisk-us.com</p>
<p>Revised: March 2013</p>
<p><span class="Bold">PATIENT INSTRUCTIONS FOR USE</span></p>
<p><span class="Bold">NovoLog</span><span class="Sup">®</span><span class="Bold">3 mL PenFill cartridge (100 Units/mL, U-100)
                                <span class="Sup">®</span></span></p>
<p><span class="Bold">Before using the NovoLog cartridge
                                <span class="Sup">®</span></span></p>
<dl>
<dt>1.</dt>
<dd>Talk with your healthcare provider for information about where to inject NovoLog (injection sites) and how to give an injection with your insulin delivery device.
                                <span class="Sup">®</span>
</dd>
<dt>2.</dt>
<dd>Read the instruction manual that comes with your insulin delivery device for complete instructions on how to use the PenFill cartridge with the device.
                                <span class="Sup">®</span>
</dd>
</dl>
<p><span class="Bold">How to use the NovoLog cartridge
                                <span class="Sup">®</span></span></p>
<dl>
<dt>1.</dt>
<dd>Just before using your NovoLog cartridge, check to make sure that you have the right type of insulin. This is especially important if you use different types of insulin.
                                <span class="Bold">Check your insulin.</span><span class="Sup">®</span>
</dd>
<dt>2.</dt>
<dd>The insulin should be clear and colorless. The tamper-resistant foil should be in place before the first use. If the foil has been broken or removed before your first use of the cartridge, or if the insulin is cloudy or colored, do not use it. Call Novo Nordisk at 1-800-727-6500.
                                <span class="Bold">Carefully look at the cartridge and the insulin inside it.</span>
</dd>
<dt>3.</dt>
<dd>well with soap and water. If you clean your injection site with an alcohol swab, let the injection site dry before you inject. Talk with your healthcare provider for guidance on injection sites and how to give an injection with your insulin delivery device.
                                <span class="Bold">Wash your hands</span>
</dd>
<dt>4.</dt>
<dd>Gather your supplies for injecting NovoLog .
                                <span class="Sup">®</span>
</dd>
<dt>5.</dt>
<dd>Insert a 3 mL cartridge into your Novo Nordisk 3 mL PenFill cartridge compatible insulin delivery device. Wipe the front rubber stopper of the 3 mL PenFill cartridge with an alcohol swab, then attach a new needle. For NovoFine needles, remove the big outer needle cap and the inner needle cap. Always use a new needle for each injection to prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.
                                <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span>
</dd>
</dl>
<p><span class="Bold">Giving the airshot before each injection:</span></p>
<p>To prevent the injection of air and to make sure insulin is delivered, you must do an airshot before each injection. Hold the device with the needle pointing up and gently tap the PenFill cartridge holder with your finger a few times to raise any air bubbles to the top of the cartridge. Do the airshot as described in the device instruction manual.
                            <span class="Sup">®</span></p>
<p><span class="Bold">Giving the injection</span></p>
<p>6. Dial the number of units on the insulin delivery device that you need to inject. Inject the right way as shown to you by your healthcare provider.</p>
<p>7. Insert the needle into the skin. Inject the dose by pressing the push button all the way in. Keep the needle in the skin for at least 6 seconds, and keep the push button pressed all the way in until the needle has been pulled out from the skin. This will make sure that the full dose has been given. You may see a drop of NovoLog at the needle tip. This is normal and has no effect on the dose you just received. If blood appears after you take the needle out of your skin, press the injection site lightly with a finger.
                            <span class="Sup">®</span><span class="Bold">Do not rub the area.</span></p>
<p><span class="Bold">After the injection</span></p>
<p>8. Recapping can lead to a needle stick injury.
                            <span class="Bold">Do not recap the needle.</span></p>
<p>9. Remove the needle from the PenFill cartridge after each injection. Keep the 3 mL PenFill cartridge in the insulin delivery device. The needle should not be attached to the 3 mL PenFill cartridge during storage. This will prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or leakage of insulin and will help ensure that you receive the right dose of NovoLog .
                            <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span></p>
<p>10. Put the used needle and cartridge in a sharps container, or some type of hard plastic or metal container with a screw on top such as a detergent bottle or coffee can. Check with your healthcare provider about the right way to throw away used needles and cartridges. There may be local or state laws about how to throw away used needles and syringes. Do not throw used needles and cartridges in household trash or recycling bins.</p>
<p>11. Put the pen cap back on the Novo Nordisk 3 mL PenFill cartridge compatible insulin delivery device.
                            <span class="Sup">®</span></p>
<p>Date of Issue: March 2013</p>
<p>Version: 9</p>
<p><span class="Italics">Novo Nordisk , NovoLog , PenFill , and NovoFine are registered trademarks of Novo Nordisk A/S.
                                <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span></span></p>
<p>NovoLog is covered by US Patent Nos. 5,618,913, 5,866,538, and other patents pending.
                            <span class="Sup">®</span></p>
<p>PenFill is covered by US Patent No. 5,693,027.
                            <span class="Sup">®</span></p>
<p>© 2002-2013 Novo Nordisk</p>
<p>Manufactured by:</p>
<p>Novo Nordisk A/S</p>
<p>DK-2880 Bagsvaerd, Denmark</p>
<p>For information about NovoLog contact:
                            <span class="Sup">®</span></p>
<p>Novo Nordisk Inc.</p>
<p>800 Scudders Mill Road</p>
<p>Plainsboro, New Jersey 08536</p>
<p><span class="Bold">PATIENT INSTRUCTIONS FOR USE</span></p>
<p><span class="Bold">NovoLog (NŌ-v?-log)FlexTouch Pen
                                <span class="Sup">®</span><span class="Sup">®</span></span></p>
<p>(insulin aspart [rDNA origin] injection)</p>
<dl>
<dt>•</dt>
<dd>containing 300 units of U-100 NovoLog (insulin aspart [rDNA origin] injection) insulin. You can inject from 1 to 80 units in a single injection.
                                <span class="Bold">NovoLog FlexTouch Pen (“Pen?) is a prefilled disposable pen</span>
</dd>
<dt>•</dt>
<dd><span class="Bold">Do not share your NovoLog FlexTouch Pen with another person. You may give an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to them or get an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> from them.</span></dd>
<dt>•</dt>
<dd><span class="Bold">This Pen is not recommended for use by the blind or visually impaired without the assistance of a person trained in the proper use of the product.</span></dd>
</dl>
<p><span class="Bold">Supplies you will need to give your NovoLog injection:</span></p>
<dl>
<dt>•</dt>
<dd>NovoLog FlexTouch Pen
                                </dd>
<dt>•</dt>
<dd>a new NovoFine or NovoTwist needle
                                </dd>
<dt>•</dt>
<dd>alcohol swab
                                </dd>
<dt>•</dt>
<dd>1 sharps container for throwing away used Pens and needles.
                                <span class="Bold">See “Disposing of used NovoLog FlexTouch Pens and needles? at the end of these instructions.</span>
</dd>
</dl>
<p><span class="Bold">Preparing your NovoLog FlexTouch Pen:</span></p>
<dl>
<dt>•</dt>
<dd>Wash your hands with soap and water.
                                </dd>
<dt>•</dt>
<dd><span class="Bold">Before you start to prepare your injection, check the NovoLog FlexTouch Pen label to make sure you are taking the right type of insulin. This is especially important if you take more than 1 type of insulin.</span></dd>
<dt>•</dt>
<dd>NovoLog should look clear and colorless. use NovoLog if it is thick, cloudy, or is colored.
                                <span class="Bold">Do not</span>
</dd>
<dt>•</dt>
<dd>use NovoLog past the expiration date printed on the label or 28 days after you start using the Pen.
                                <span class="Bold">Do not</span>
</dd>
<dt>•</dt>
<dd><span class="Bold">Always use a new needle for each injection to help ensure <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> and prevent blocked needles.</span></dd>
</dl>
<div class="Figure">
<a name="id-233695268"></a><img alt="NovoFine, NovoTwist and NovoLog Flextouch parts" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-20.jpg">
</div>
<p><span class="Bold">Step 1:</span></p>
<dl>
<dt>•</dt>
<dd>Pull Pen cap straight off (See Figure B).
                                </dd>
</dl>
<div class="Figure">
<a name="id-258605066"></a><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-21.jpg">
</div>
<p>(Figure B)</p>
<p><span class="Bold">Step 2:</span></p>
<dl>
<dt>•</dt>
<dd>(See Figure C). NovoLog should look clear and colorless. use it if it looks cloudy or colored.
                                <span class="Bold">Check the liquid in the Pen</span><span class="Bold">Do not</span>
</dd>
</dl>
<div class="Figure">
<a name="id-1335372906"></a><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-22.jpg">
</div>
<p>(Figure C)</p>
<p><span class="Bold">Step 3:</span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Select a new needle.</span></dd>
<dt>•</dt>
<dd>Pull off the paper tab from the outer needle cap (See Figure D).
                                </dd>
</dl>
<div class="Figure">
<a name="id1981574784"></a><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-23.jpg">
</div>
<p>(Figure D)</p>
<p><span class="Bold">Step 4:</span></p>
<dl>
<dt>•</dt>
<dd>Push the capped needle straight onto the Pen and twist the needle on until it is tight (See Figure E).
                                </dd>
</dl>
<div class="Figure">
<a name="id-432274022"></a><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-24.jpg">
</div>
<p>(Figure E)</p>
<p><span class="Bold">Step 5:</span></p>
<dl>
<dt>•</dt>
<dd>Pull off the outer needle cap. throw it away (See Figure F).
                                <span class="Bold">Do not</span>
</dd>
</dl>
<div class="Figure">
<a name="id703605799"></a><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-25.jpg">
</div>
<p>(Figure F)</p>
<p><span class="Bold">Step 6:</span></p>
<dl>
<dt>•</dt>
<dd>Pull off the inner needle cap and throw it away (See Figure G).
                                </dd>
</dl>
<div class="Figure">
<a name="id-1795902006"></a><img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-26.jpg">
</div>
<p>(Figure G)</p>
<p><span class="Bold">Priming your NovoLog FlexTouch Pen:</span></p>
<p><span class="Bold">Step 7:</span></p>
<dl>
<dt>•</dt>
<dd>Turn the dose selector to (See Figure H).
                                <span class="Bold">select 2 units</span>
</dd>
</dl>
<div class="Figure">
<a name="id403103108"></a><img alt="Figure H" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-27.jpg">
</div>
<p>(Figure H)</p>
<p><span class="Bold">Step 8:</span></p>
<dl>
<dt>•</dt>
<dd>Hold the Pen with the needle pointing up. Tap the top of the Pen gently a few times to let any air bubbles rise to the top (See Figure I).
                                </dd>
</dl>
<div class="Figure">
<a name="id142172560"></a><img alt="Figure I" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-28.jpg">
</div>
<p>(Figure I)</p>
<p><span class="Bold">Step 9:</span></p>
<dl>
<dt>•</dt>
<dd>Press and hold in the dose button until the dose counter shows “0?. The “0? must line up with the dose pointer.
                                <span class="Bold">Hold the Pen with the needle pointing up.</span>
</dd>
<dt>•</dt>
<dd>A drop of insulin should be seen at the needle tip (See Figure J).
                                <dl>
<dt>•</dt>
<dd>If you see a drop of insulin, repeat steps 7 to 9, no more than 6 times.
                                        <span class="Bold">do not</span>
</dd>
<dt>•</dt>
<dd>If you see a drop of insulin, change the needle and repeat steps 7 to 9.
                                        <span class="Bold">still do not</span>
</dd>
</dl>
</dd>
</dl>
<div class="Figure">
<a name="id1338957272"></a><img alt="Figure J" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-29.jpg">
</div>
<p>(Figure J)</p>
<p><span class="Bold">Selecting your dose:</span></p>
<p><span class="Bold">Step 10:</span></p>
<dl>
<dt>•</dt>
<dd>The dose pointer should line up with your dose (See Figure K).
                                <span class="Bold">Turn the dose selector to select the number of units you need to inject.</span><dl>
<dt>•</dt>
<dd>If you select the wrong dose, you can turn the dose selector forwards or backwards to the correct dose.
                                        </dd>
<dt>•</dt>
<dd>The numbers are printed on the dial.
                                        <span class="Bold">even</span>
</dd>
<dt>•</dt>
<dd>The numbers are shown as lines.
                                        <span class="Bold">odd</span>
</dd>
</dl>
</dd>
</dl>
<div class="Figure">
<a name="id800270676"></a><img alt="Figure K" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-30.jpg">
</div>
<p>(Figure K)</p>
<dl>
<dt>•</dt>
<dd>The NovoLog FlexTouch Pen insulin scale will show you how much insulin is left in your Pen (See Figure L).
                                </dd>
<dt>•</dt>
<dd>
<span class="Bold">To see how much insulin is left in your NovoLog FlexTouch Pen:</span><dl>
<dt>•</dt>
<dd>Turn the dose selector until it stops. The dose counter will line up with the number of units of insulin that is left in your Pen. If the dose counter shows 80, there are units left in your Pen.
                                        <span class="Bold">at least 80</span>
</dd>
<dt>•</dt>
<dd>If the dose counter shows the number shown in the dose counter is the number of units left in your Pen.
                                        <span class="Bold">less than 80,</span>
</dd>
</dl>
</dd>
</dl>
<div class="Figure">
<a name="id-1940669504"></a><img alt="Figure L" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-31.jpg">
</div>
<p>(Figure L)</p>
<p><span class="Bold">Giving your injection:</span></p>
<dl>
<dt>•</dt>
<dd>Inject your NovoLog exactly as your healthcare provider has shown you. Your healthcare provider should tell you if you need to pinch the skin before injecting.
                                </dd>
<dt>•</dt>
<dd>NovoLog can be injected under the skin (subcutaneously) of your stomach area (abdomen), buttocks, upper legs (thighs) or upper arms.
                                </dd>
<dt>•</dt>
<dd>Change (rotate) your injection sites within the area you choose for each dose. use the same injection site for each injection.
                                <span class="Bold">Do not</span>
</dd>
</dl>
<p><span class="Bold">Step 11:</span></p>
<dl>
<dt>•</dt>
<dd>Choose your injection site and wipe the skin with an alcohol swab. Let the injection site dry before you inject your dose (See Figure M).
                                </dd>
</dl>
<div class="Figure">
<a name="id-1618980364"></a><img alt="Figure M" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-32.jpg">
</div>
<p>(Figure M)</p>
<p><span class="Bold">Step 12:</span></p>
<dl>
<dt>•</dt>
<dd>(See Figure N).
                                <span class="Bold">Insert the needle into your skin</span><dl>
<dt>•</dt>
<dd>cover it with your fingers, this can stop your injection.
                                        <span class="Bold">Make sure you can see the dose counter. Do not</span>
</dd>
</dl>
</dd>
</dl>
<div class="Figure">
<a name="id471955781"></a><img alt="Figure N" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-33.jpg">
</div>
<p>(Figure N)</p>
<p><span class="Bold">Step 13:</span></p>
<dl>
<dt>•</dt>
<dd>(See Figure O).
                                <span class="Bold">Press and hold down the dose button until the dose counter shows “0?</span><dl>
<dt>•</dt>
<dd>The “0? must line up with the dose pointer. You may then hear or feel a click.
                                        </dd>
</dl>
</dd>
</dl>
<div class="Figure">
<a name="id-643423219"></a><img alt="Figure O" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-34.jpg">
</div>
<p>(Figure O)</p>
<dl>
<dt>•</dt>
<dd>the dose counter has returned to “0? and (See Figure P).
                                <span class="Bold">Keep the needle in your skin after</span><span class="Bold">slowly count to 6</span>
</dd>
</dl>
<div class="Figure">
<a name="id1551730302"></a><img alt="Figure P" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-35.jpg">
</div>
<p>(Figure P)</p>
<dl>
<dt> </dt>
<dd><dl>
<dt>•</dt>
<dd><span class="Bold">When the dose counter returns to “0?, you will not get your full dose until 6 seconds later.</span></dd>
<dt>•</dt>
<dd><span class="Bold">If the needle is removed before you count to 6, you may see a stream of insulin coming from the needle tip.</span></dd>
<dt>•</dt>
<dd><span class="Bold">If you see a stream of insulin coming from the needle tip you will not get your full dose. If this happens you should check your blood sugar levels more often because you may need more insulin.</span></dd>
</dl></dd>
</dl>
<p><span class="Bold">Step 14:</span></p>
<dl>
<dt>•</dt>
<dd>(See Figure Q).
                                <span class="Bold">Pull the needle out of your skin</span><dl>
<dt>•</dt>
<dd>If you see blood after you take the needle out of your skin, press the injection site lightly with a piece of gauze or an alcohol swab. rub the area.
                                        <span class="Bold">Do not</span>
</dd>
</dl>
</dd>
</dl>
<div class="Figure">
<a name="id252481062"></a><img alt="Figure Q" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-36.jpg">
</div>
<p>(Figure Q)</p>
<p><span class="Bold">Step 15:</span></p>
<dl>
<dt>•</dt>
<dd>(See Figure R).
                                <span class="Bold">Carefully remove the needle from the Pen and throw it away</span><dl>
<dt>•</dt>
<dd>recap the needle. Recapping the needle can lead to needle stick injury.
                                        <span class="Bold">Do not</span>
</dd>
</dl>
</dd>
</dl>
<div class="Figure">
<a name="id2065835753"></a><img alt="Figure R" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-37.jpg">
</div>
<p>(Figure R)</p>
<dl>
<dt>•</dt>
<dd>If you have a sharps container, carefully slip the needle into the outer needle cap (See Figure S). Safely remove the needle and throw it away as soon as you can.
                                <span class="Bold">do not</span>
</dd>
</dl>
<div class="Figure">
<a name="id1543251496"></a><img alt="Figure S" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-38.jpg">
</div>
<p>(Figure S)</p>
<dl>
<dt> </dt>
<dd><dl>
<dt>•</dt>
<dd>store the Pen with the needle attached. Storing without the needle attached helps prevent leaking, blocking of the needle, and air from entering the Pen.
                                        <span class="Bold">Do not</span>
</dd>
</dl></dd>
</dl>
<p><span class="Bold">Step 16:</span></p>
<dl>
<dt>•</dt>
<dd>Replace the Pen cap by pushing it straight on (See Figure T).
                                </dd>
</dl>
<div class="Figure">
<a name="id1925458645"></a><img alt="Figure T" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-39.jpg">
</div>
<p>(Figure T)</p>
<p><span class="Bold">After your injection:</span></p>
<dl>
<dt>•</dt>
<dd>Put your used NovoLog FlexTouch Pen and needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and Pens in your household trash.
                                </dd>
<dt>•</dt>
<dd>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
                                <dl>
<dt>•</dt>
<dd>made of a heavy-duty plastic
                                        </dd>
<dt>•</dt>
<dd>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out
                                        </dd>
<dt>•</dt>
<dd>upright and stable during use
                                        </dd>
<dt>•</dt>
<dd>leak-resistant
                                        </dd>
<dt>•</dt>
<dd>properly labeled to warn of hazardous waste inside the container
                                        </dd>
</dl>
</dd>
<dt>•</dt>
<dd>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about the safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: .
                                <a href="http://www.fda.gov/safesharpsdisposal">http://www.fda.gov/safesharpsdisposal</a>
</dd>
<dt>•</dt>
<dd>Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
                                </dd>
</dl>
<p><span class="Bold">How should I store my NovoLog FlexTouch Pen?</span></p>
<dl>
<dt>•</dt>
<dd>Store unused NovoLog FlexTouch Pens in the refrigerator at 36°F to 46°F (2°C to 8°C).
                                </dd>
<dt>•</dt>
<dd>Store the Pen you are currently using out of the refrigerator below 86°F.
                                </dd>
<dt>•</dt>
<dd>freeze NovoLog. use NovoLog if it has been frozen.
                                <span class="Bold">Do not</span><span class="Bold">Do not</span>
</dd>
<dt>•</dt>
<dd>Keep NovoLog away from heat or light.
                                </dd>
<dt>•</dt>
<dd>Unused Pens may be used until the expiration date printed on the label, if kept in the refrigerator.
                                </dd>
<dt>•</dt>
<dd>The NovoLog FlexTouch Pen you are using should be thrown away after 28 days, even if it still has insulin left in it.
                                </dd>
</dl>
<p><span class="Bold">General Information about the safe and effective use of NovoLog.</span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Keep NovoLog FlexTouch Pens and needles out of the reach of children.</span></dd>
<dt>•</dt>
<dd>use a new needle for each injection.
                                <span class="Bold">Always</span>
</dd>
<dt>•</dt>
<dd>share Pens or needles.
                                <span class="Bold">Do not</span>
</dd>
</dl>
<p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Manufactured By:</span></p>
<p>Novo Nordisk A/S</p>
<p>DK-2880 Bagsvaerd, Denmark</p>
<p><span class="Bold">Revised: 10/2013</span></p>
<p><span class="Bold">PATIENT INSTRUCTIONS FOR USE</span></p>
<p><span class="Bold">NovoLog FlexPen
                                <span class="Sup">®</span></span><span class="Sup">®</span></p>
<p><span class="Bold">Introduction</span></p>
<p>Please read the following instructions carefully before using your NovoLog FlexPen .
                            <span class="Sup">®</span><span class="Sup">®</span></p>
<p>NovoLog FlexPen is a disposable dial-a-dose insulin pen. You can select doses from 1 to 60 units in increments of 1 unit. NovoLog FlexPen is designed to be used with NovoFine needles.
                            <span class="Sup">®</span></p>
<dl>
<dt> </dt>
<dd>NovoLog FlexPen should not be used by people who are blind or have severe visual problems without the help of a person who has good eyesight and who is trained to use the NovoLog FlexPen the right way.
                                <span class="Sup">Δ</span>
</dd>
</dl>
<p><span class="Bold">Getting ready</span></p>
<p>Make sure you have the following items:</p>
<dl>
<dt>•</dt>
<dd>NovoLog FlexPen
                                </dd>
<dt>•</dt>
<dd>New NovoFine needle
                                </dd>
<dt>•</dt>
<dd>Alcohol swab
                                </dd>
</dl>
<div class="Figure">
<a name="id2321"></a><img alt="NovoLog FlexPen Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-40.jpg">
</div>
<div class="Figure">
<a name="id-1737854575"></a><img alt="NovoFine Needle Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-41.jpg">
</div>
<p><span class="Bold">Preparing Your NovoLog FlexPen</span></p>
<p>Wash your hands with soap and water. Before you start to prepare your injection, check the label to make sure that you are taking the right type of insulin. This is especially important if you take more than 1 type of insulin. NovoLog should look clear.</p>
<p>. Pull off the pen cap (see diagram A).
                            <span class="Bold">A</span></p>
<div class="Figure">
<a name="id2327"></a><img alt="A - Preparing the NovoLog FlexPen" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-42.jpg">
</div>
<p>Wipe the rubber stopper with an alcohol swab.</p>
<p><span class="Bold">B. Attaching the needle</span></p>
<p> Remove the protective tab from a disposable needle.</p>
<p>Screw the needle tightly onto your FlexPen. It is important that the needle is put on straight (see diagram B).</p>
<div class="Figure">
<a name="id2333"></a><img alt="B - Attaching the Needle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-43.jpg">
</div>
<p>Never place a disposable needle on your NovoLog FlexPen until you are ready to take your injection.</p>
<p>Pull off the big outer needle cap (see diagram C).
                            <span class="Bold">C.</span></p>
<div class="Figure">
<a name="id2337"></a><img alt="C - Pulling off the big outer needle cap" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-44.jpg">
</div>
<p>Pull off the inner needle cap and dispose of it (see diagram D).
                            <span class="Bold">D.</span></p>
<div class="Figure">
<a name="id2340"></a><img alt="D - Pulling off the inner needle cap" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-45.jpg">
</div>
<dl>
<dt> </dt>
<dd>Always use a new needle for each injection to help ensure <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> and prevent blocked needles.
                                <span class="Bold">Δ</span>
</dd>
<dt> </dt>
<dd>Be careful not to bend or damage the needle before use.
                                <span class="Bold">Δ</span>
</dd>
<dt> </dt>
<dd>To reduce the risk of unexpected needle sticks, never put the inner needle cap back on the needle.
                                <span class="Bold">Δ</span>
</dd>
</dl>
<p><span class="Bold">Giving the airshot before each injection</span></p>
<p>Before each injection small amounts of air may collect in the cartridge during normal use. To avoid injecting air and to ensure proper dosing:</p>
<p>Turn the dose selector to select 2 units (see diagram E).
                            <span class="Bold">E.</span></p>
<div class="Figure">
<a name="id2356"></a><img alt="E - Giving the airshot before each injection- Turn the dose selector to select 2 units" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-46.jpg">
</div>
<p>Hold your NovoLog FlexPen with the needle pointing up. Tap the cartridge gently with your finger a few times to make any air bubbles collect at the top of the cartridge (see diagram F).
                            <span class="Bold">F.</span></p>
<div class="Figure">
<a name="id2359"></a><img alt="F - Giving the airshot before each injection - Tap the cartridge to make air bubbles collect at the top of the cartridge" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-47.jpg">
</div>
<p>Keep the needle pointing upwards, press the push-button all the way in (see diagram G). The dose selector returns to 0.
                            <span class="Bold">G.</span></p>
<div class="Figure">
<a name="id2362"></a><img alt="G - Giving the airshot before each injection - Press the push-button all the way in. The dose selector returns to 0" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-48.jpg">
</div>
<p>A drop of insulin should appear at the needle tip. If not, change the needle and repeat the procedure no more than 6 times.</p>
<p>If you do not see a drop of insulin after 6 times, do not use the NovoLog FlexPen and contact Novo Nordisk at 1-800-727-6500.</p>
<p>A small air bubble may remain at the needle tip, but it will not be injected.</p>
<p><span class="Bold">Selecting your dose</span></p>
<p>Check and make sure that the dose selector is set at 0.</p>
<p>Turn the dose selector to the number of units you need to inject. The pointer should line up with your dose.
                            <span class="Bold">H.</span></p>
<p>The dose can be corrected either up or down by turning the dose selector in either direction until the correct dose lines up with the pointer (see diagram H). When turning the dose selector, be careful not to press the push-button as insulin will come out.</p>
<div class="Figure">
<a name="id2372"></a><img alt="H - Selecting the dose" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-49.jpg">
</div>
<p>You cannot select a dose larger than the number of units left in the cartridge.</p>
<p>You will hear a click for every single unit dialed. Do not set the dose by counting the number of clicks you hear.</p>
<dl>
<dt> </dt>
<dd>Δ Do not use the cartridge scale printed on the cartridge to measure your dose of insulin.
                                </dd>
</dl>
<p><span class="Bold">Giving the injection</span></p>
<p>Do the injection exactly as shown to you by your healthcare provider. Your healthcare provider should tell you if you need to pinch the skin before injecting.</p>
<p>Insert the needle into your skin.
                            <span class="Bold">I.</span></p>
<p>Inject the dose by pressing the push-button all the way in until the 0 lines up with the pointer (see diagram I). Be careful only to push the button when injecting.</p>
<div class="Figure">
<a name="id2384"></a><img alt="I - Giving the injection" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-50.jpg">
</div>
<p>Turning the dose selector will not inject insulin.</p>
<p>Keep the needle in the skin for at least 6 seconds, and keep the push-button pressed all the way in until the needle has been pulled out from the skin (see diagram J). This will make sure that the full dose has been given.
                            <span class="Bold">J.</span></p>
<p>You may see a drop of NovoLog at the needle tip. This is normal and has no effect on the dose you just received. If blood appears after you take the needle out of your skin, press the injection site lightly with a finger.
                            <span class="Bold">Do not rub the area.</span></p>
<div class="Figure">
<a name="id2390"></a><img alt="J - Giving the injection - Making sure that the full dose has been given" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-51.jpg">
</div>
<p><span class="Bold">After the injection</span></p>
<p>Recapping can lead to a needle stick injury.  Remove the needle from the NovoLog FlexPen after each injection. This helps to prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, leakage of insulin, and will help to make sure you inject the right dose of insulin.
                            <span class="Bold">Do not recap the needle.</span></p>
<dl>
<dt> </dt>
<dd>Put the needle and any empty NovoLog FlexPen or any used NovoLog FlexPen still containing insulin in a sharps container or some type of hard plastic or metal container with a screw top such as a detergent bottle or empty coffee can. These containers should be sealed and thrown away the right way. Check with your healthcare provider about the right way to throw away used syringes and needles.  There may be local or state laws about how to throw away used needles and syringes. Do not throw away used needles and syringes in household trash or recycling bins.
                                <span class="Bold">Δ</span>
</dd>
</dl>
<p>The NovoLog FlexPen prevents the cartridge from being completely emptied. It is designed to deliver 300 units.</p>
<p>. Put the pen cap on the NovoLog FlexPen and store the NovoLog FlexPen without the needle attached (see diagram K).
                            <span class="Bold">K</span></p>
<div class="Figure">
<a name="id2402"></a><img alt="K - After the injection - Storing NovoLog FlexPen" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-52.jpg">
</div>
<p><span class="Bold">L Function Check</span></p>
<p>If your NovoLog FlexPen is not working the right way, follow the steps below:</p>
<dl>
<dt>•</dt>
<dd>Screw on a new NovoFine needle.
                                </dd>
<dt>•</dt>
<dd>Remove the big outer needle cap and the inner needle cap.
                                </dd>
<dt>•</dt>
<dd>Do an airshot as described in "Giving the airshot before each injection".
                                </dd>
<dt>•</dt>
<dd>Put the big outer needle cap onto the needle. Do not put on the inner needle cap.
                                </dd>
<dt>•</dt>
<dd>Turn the dose selector so the dose indicator window shows 20 units.
                                </dd>
<dt>•</dt>
<dd>Hold the NovoLog FlexPen so the needle is pointing down.
                                </dd>
<dt>•</dt>
<dd>Press the push-button all the way in.
                                </dd>
</dl>
<p>The insulin should fill the lower part of the big outer needle cap (see diagram L). If the NovoLog FlexPen has released too much or too little insulin, do the function check again. If the same problem happens again, do not use your NovoLog FlexPen and contact Novo Nordisk at 1-800-727-6500.</p>
<div class="Figure">
<a name="id2416"></a><img alt="L - Function Check" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=39c679b5-960c-4c65-8306-2cbb6a9469b2-53.jpg">
</div>
<p><span class="Bold">Maintenance</span></p>
<p>Your FlexPen is designed to work accurately and safely. It must be handled with care. Avoid dropping your FlexPen as it may damage it. If you are concerned that your FlexPen is damaged, use a new one. You can clean the outside of your FlexPen by wiping it with a damp cloth. Do not soak or wash your FlexPen as it may damage it. Do not refill your FlexPen.</p>
<p>Remove the needle from the NovoLog FlexPen after each injection. This helps to ensure <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span>, prevent leakage of insulin, and will help to make sure you inject the right dose of insulin for future injections.
                            <span class="Bold">Δ</span></p>
<p>Be careful when handling used needles to avoid needle sticks and transfer of infectious diseases.
                            <span class="Bold">Δ</span></p>
<p>Keep your NovoLog FlexPen and needles out of the reach of children.
                            <span class="Bold">Δ</span></p>
<p>Use NovoLog FlexPen as directed to treat your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Needles and NovoLog FlexPen must not be shared.
                            <span class="Bold">Δ</span></p>
<p>Always use a new needle for each injection.
                            <span class="Bold">Δ</span></p>
<p>Novo Nordisk is not responsible for harm due to using this insulin pen with products not recommended by Novo Nordisk.
                            <span class="Bold">Δ</span></p>
<p>As a precautionary measure, always carry a spare insulin delivery device in case your NovoLog FlexPen is lost or damaged.
                            <span class="Bold">Δ</span></p>
<p>Remember to keep the disposable NovoLog FlexPen with you. Do not leave it in a car or other location where it can get too hot or too <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>.
                            <span class="Bold">Δ</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66472b3d-32c1-4803-aff4-b621aa5430b3&amp;name=64725-0750.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NOVOLOG 		
					</strong><br><span class="contentTableReg">insulin aspart injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64725-0750(NDC:0169-7501)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>INSULIN ASPART</strong> (INSULIN ASPART) </td>
<td class="formItem">INSULIN ASPART</td>
<td class="formItem">100 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC, DIHYDRATE</strong></td>
<td class="formItem">1.25 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">16 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METACRESOL</strong></td>
<td class="formItem">1.72 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">1.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">0.58 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ZINC</strong></td>
<td class="formItem">19.6 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64725-0750-1</td>
<td class="formItem">10 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020986</td>
<td class="formItem">08/27/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>TYA Pharmaceuticals
							(938389038)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>TYA Pharmaceuticals (938389038)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">TYA Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">938389038</td>
<td class="formItem">RELABEL(64725-0750), REPACK(64725-0750)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f92b7a9d-49f8-4b5e-9598-7d2c606ff62f</div>
<div>Set id: 66472b3d-32c1-4803-aff4-b621aa5430b3</div>
<div>Version: 2</div>
<div>Effective Time: 20140425</div>
</div>
</div> <div class="DistributorName">TYA Pharmaceuticals</div></p>
</body></html>
